

Curriculum Vitae

MICHAEL PAUL LINK



EDUCATION:

	<u>Degree</u>	<u>Year</u>
Columbia College, New York, New York	A.B.	1970
Stanford University School of Medicine, Stanford, California	M.D.	1974

MEDICAL LICENSES:

Commonwealth of Massachusetts [ ]  
State of California

BOARD CERTIFICATION:

Diplomate: National Board of Medical Examiners, OSA  
American Board of Pediatrics, awarded October 21, 1979 \_\_\_\_\_  
American Board of Pediatrics, Sub-Board of Pediatric Hematology/Oncology, awarded  
October 10, 1980, \_\_\_\_\_

HONORS:

Graduate Summa Cum Laude, Columbia College	1970
Phi Beta Kappa	1969
Alpha Omega Alpha	1974
Listed in <i>The Best Doctors in America</i> (Woodward/White)	1992-
Listed in <i>The Best Doctors in America: Pacific Region</i> (Woodward/White)	1996-
Listed in AMERICAN HEALTH's "Best Doctors in America	1996-
13 <sup>th</sup> Ben Abelson Memorial Visiting Professor at Washington University School of Medicine	May 11-12, 2000

12<sup>th</sup> Annual Pediatric Cancer Research Foundation  
Memorial Lectureship

January 19, 2004

**MEMBERSHIPS:**

American Academy of Pediatrics  
American Society of Clinical Oncology  
American Society of Hematology  
American Association of Cancer Research  
American Society of Pediatric Hematology/Oncology  
The Society for Pediatric Research  
Société Internationale d'Oncologie Pédiatrique (SIOP)  
American Pediatric Society  
Connective Tissue Oncology Society

**HOSPITAL AND ACADEMIC APPOINTMENTS:**

Intern in Medicine, Children's Hospital Medical Center, Boston, Massachusetts	July 1974 - June 1975
Junior Assistant Resident in Medicine, Children's Hospital Medical Center, Boston, Massachusetts	July 1975 - June 1976
Clinical Fellow in Pediatrics, Harvard University Boston, Massachusetts	July 1974 - June 1976
Research Fellow in Pediatrics, Harvard University Boston, Massachusetts	July 1976 - June 1979
Fellow in Medicine (Immunology), Children's Hospital Medical Center, Boston, Massachusetts	July 1976 - June 1977
Fellow in Medicine (Hematology/Oncology), Children's Hospital Medical Center, Boston, Massachusetts	July 1977 - June 1979
Fellow in Pediatric Hematology/Oncology, Dana Farber Cancer Institute, Boston, Massachusetts	July 1977 - June 1979
Assistant Professor of Pediatrics Stanford University School of Medicine, Stanford, CA	July 1979 - Dec. 1985
Associate Professor of Pediatrics Stanford University School of Medicine, Stanford, CA	Jan. 1986 - June 1991

Professor of Pediatrics (with tenure) Stanford University School of Medicine, Stanford, CA	July 1991 - Present
Staff Hematologist/Oncologist, Children's Hospital at Stanford, Palo Alto, California.	July 1979 - Present
Co-Director, Oncology Program, Lucile Salter Packard Children's Hospital at Stanford, Palo Alto, California	June 1990 - June, 2000
Chief, Division of Pediatric Oncology, Hematology and Bone Marrow Transplantation	August 2000 - Present
Director, Oncology, Hematology and Bone Marrow Transplant Program, Lucile Salter Packard Children's Hospital at Stanford, Palo Alto, California	August 2000 - Present
Lydia J. Lee Professor in Pediatric Cancer. Stanford University School of Medicine	June 2003 - Present

#### RELATED PROFESSIONAL ACTIVITIES:

Principal Investigator, Pediatric Oncology Group	1984 - 2000
Chairman, Pediatric Oncology Group Bone and Soft Tissue Sarcoma Committee	1984 - 1993
Site Visitor, Children's Cancer Study Group	April, 1988
PDQ Pediatric Cancer Treatment Editorial Advisory Board	1991 - present
American Cancer Society Task Force on Children and Cancer	1991 - 1994; 1996 - present
Journal of Clinical Oncology Editorial Board	1992 - 1994
Site Visitor, Intramural Pediatrics Branch, National Cancer Institute, National Institutes of Health	March, 1993
Vice-Chairman, Pediatric Oncology Group	1993 - 2000
Chairman, Pediatric Oncology Group Data Monitoring Committee	1993 - 2001
Intergroup Rhabdomyosarcoma Study Group Steering Committee	1993 - 2000
Principal Investigator, Childhood Cancer Survivor Study Group	1993 - present
American Society of Clinical Oncology--Public Issues Committee	1994 - 1998
American Society of Clinical Oncology--Program Committee	1994 - 1995
National Comprehensive Cancer Center Network Pediatric Steering Committee	1995 - present
Blue Cross Blue Shield Association Children's Cancer Network Advisory Panel	1995 - 1999
The Oncologist Journal Editorial Board	1996 - 2001
American Society of Clinical Oncology--Program Committee Pediatric Subcommittee Chairman	1996 - 1997

French/ American/ British (FAB) Study: LMB 96 Treatment of Mature B-Cell Lymphoma/Leukemia--A SFOP LMB96/CCG-5961/UKCCSG NHL International 9600 Cooperative Study Data Monitoring Committee Chairman	1996 - 2003
American Society of Clinical Oncology--Subcommittee on Cancer Care at the End of Life	1997 - present
Ad Hoc Review Group for Clinical Fellowship Program and Special Pilot Research Grant Program, American Cancer Society, California Division	1997 - present
International Advisory Board, Al-Amal Cancer Center, Amman, Jordan	1997 - 2002
Vice-Chairman, Intergroup Rhabdomyosarcoma Study Group	1998 - 2000
American Society of Clinical Oncology--Cancer Communications Committee	1998 - 2001
Site Visitor, Children's Cancer Group	June, 1998
National Cancer Institute Panel on Tissue Banking	1998 - 2000
Abstract Reviewer for the Annual Meeting of the American Pediatric Society/Society for Pediatric Research	1999
Board of Directors, American Society of Clinical Oncology	1999-2002
American Cancer Society Steering Committee for 1999 National Summit on Childhood Cancer	1999-2000
Clinical Oncology Special Emphasis Panel (Study Section), National Institutes of Health	1999 - 2001
Professional Advisory Committee of The Children's Cause	2000 - present
American Society of Clinical Oncology – Finance Committee	2000 - 2002
Principal Investigator, Children's Oncology Group	2000 - 2004
Journal of Clinical Oncology Editorial Board	2001
Associate Editor, Journal of Clinical Oncology	2001 - present
American Society of Clinical Oncology – Pediatric Tumors Subcommittee	2001 - present
American Society of Clinical Oncology – Audit Committee Chairman	2001 - 2002
American Society of Clinical Oncology – Task Force on Governance and Structure	2001 - 2002
Chairman, Children's Oncology Group Data Monitoring Committee for Solid Tumors	2001 - present
Associate Chairman, Children's Oncology Group	2001 - present
American Society of Clinical Oncology--Program Committee Pediatric Subcommittee Chairman	2001 - 2003
American Society of Clinical Oncology/ American Association For Cancer Research Workshop on Methods in Clinical Cancer Research, Vail, Colorado. Program Committee and Faculty	2001 - 2003

California Medical Association Oncology Scientific Committee of the Council of Scientific Affairs (CSA)	2001 - present
Society for Pediatric Research David G. Nathan Award Selection Committee	2001 - 2004
Chairman	2003 - 2004
National Institutes of Health State-of-the-Science Conference on Symptom Management in Cancer: Pain, Depression, and Fatigue. Panel Member	July 15-17, 2002
American Society of Clinical Oncology Special Awards Selection Committee	2002 - 2005
Board of Scientific Advisors, National Cancer Institute (NCI)	2002 - 2007
External Reviewer for Institute of Medicine Report: "Childhood Cancer Survivorship: Improving Care and Quality of Life"	2002
National Cancer Policy Board of the Institute of Medicine: "New Drugs for Children with Cancer" – A Workshop of the Committee on Shortening the Time Line for New Cancer Treatments (invited participant)	January, 2003
External Scientific Advisory Board, Children's Cancer Research Institute of the University of Texas Health Science Center at San Antonio	2003 - present
American Society of Clinical Oncology--Public Issues Committee	2003 - 2004
Cancer Therapy Evaluation Program, National Cancer Institute: "State of the Science Symposium on Acute Lymphoblastic Leukemia" (invited participant)	May 12, 2003
Euro-Ewing Study: Data and Safety Monitoring Committee	2003 - present
National Comprehensive Cancer Network (NCCN) Pediatric Supportive Care Panel	2003 - present
American Society of Clinical Oncology – Cancer Research Committee	2004 - 2006
American Association for Cancer Research--Program Committee Pediatric Subcommittee Co-Chairman	2004 - 2005
Association of American Cancer Institutes/American Association Of Cancer Research/American Society of Clinical Oncology-Sponsored Workshop: "Designing a Smart Clinical Trials System for the 21 <sup>st</sup> Century. Optimizing the Interactions Between Basic And Clinical Science" (invited participant)	September 9-11, 2004
American Society of Clinical Oncology – Membership Committee	2004 - 2007
Chairman	2005 - 2006
Faculty of 1000 Medicine: Section Head for Pediatric Oncology	2004 - present
Oncology World Congress: Advisory Board	2004 - present
American Society of Clinical Oncology – Survivorship Task Force	2005 - 2006
External Advisory Board for the Cancer Center at St. Jude Children's Research Hospital	2005 - present
National Medical Advisory Board for Curing Kids Cancer Foundation	2006 - present

Adolescent and Young Adult Progress Review Group  
(National Cancer Institute and Lance Armstrong  
Foundation, sponsors)

May, 2006

**APPEARS THIS WAY  
ON ORIGINAL**

**JOURNAL REVIEWER:**

Journal of Clinical Oncology

Blood

Cancer

Journal of the National Cancer Institute

American Journal of Pediatric Hematology/Oncology

Pediatrics

American Journal of Medicine

New England Journal of Medicine

Journal of the American Medical Association

Clinical Orthopaedics and Related Research

**APPEARS THIS WAY  
ON ORIGINAL**

## **HOSPITAL COMMITTEES:**

Administrative Panel On Human Subjects In Medical Research (Stanford University Hospital)  
1980  
Pharmacy and Therapeutics Committee (Childrens Hospital at Stanford) (Chairman) 1981  
Medical Board (Childrens Hospital at Stanford)  
Quality Assurance Committee (Childrens Hospital at Stanford) 1989-90  
Operations excellence planning steering committee 1990-1991  
Utilization Review Committee (Lucile Salter Packard Childrens Hospital at Stanford) 1991  
Code Committee (Lucile Salter Packard Childrens Hospital at Stanford) 1991-1992  
Critical Care Committee (Lucile Salter Packard Childrens Hospital at Stanford) 1992-  
Ambulatory Care Committee Clinic Chiefs Operations Group (Lucile Salter Packard  
Childrens Hospital at Stanford) 1994-1995  
Bed Aggregation Task Force 1994-1995  
Stanford Clinical Cancer Center: Steering Committee 1997-  
Children's Services Physicians Advisory Budget Committee 1999  
Stanford Hospital and Clinics Cancer Committee 2000-2002

## **UNIVERSITY AND DEPARTMENTAL ACTIVITIES:**

---

Intern Selection Committee (Chairman) 1991-1994  
Pediatric Housestaff Curriculum Committee 1992-1994  
Pediatric Faculty Practice Plan Committee 1992  
American Cancer Society Institutional Research Grant Committee 1992-1995  
American Cancer Society Institutional Research Grant Committee, Chairman  
and Principal Investigator 1995-1999  
Faculty Search Committees for Divisions of Infectious Disease, Hematology/Oncology,  
Nephrology, Neonatology, Gastroenterology 1984-1995  
Child Health Research Fund Advisory Committee 1996-  
Faculty Search Committee for Director of Clinical Cancer Center 1995-1996  
Special Search Committee for Chairman, Department of Medicine 1996  
Ad Hoc Academic Medical Senate Committee on Academic Priorities--Subcommittee on  
Stanford Medical School Academic Priorities 1996  
Committee for Cancer Research Development 1999  
Department of Pediatrics Appointments and Promotions Committee 2000-



**PAST GRANT SUPPORT:**

NIH CA 21555

Oncology Training Grant

Principal Investigator:  
Entire Period of Support:  
Position:  
Percent Effort:

Saul Rosenberg, M.D.  
07/01/80 - 06/30/84  
Associate Investigator  
6-20%

NIH U10 CA33603

Pediatric Oncology Group

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Bertil E. Glader, Ph.D., M.D.  
01/01/83 - 12/31/84  
15%

NIH U10 CA33603

Pediatric Oncology Group

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Michael P. Link, M.D.  
01/1/85 - 12/31/85  
15%

NIH U10 CA33603

Pediatric Oncology Group

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Michael P. Link, M.D.  
01/1/86 - 03/31/91  
20%

NIH U10 CA30969

Pediatric Oncology Group  
Reference Laboratory

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Michael P. Link, M.D.  
01/1/86 - 03/31/91  
5%

NIH U10 CA30969

Pediatric Oncology Group  
Sarcoma Committee Chairman

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Michael P. Link, M.D.  
01/1/86 - 03/31/91  
5%

NIH PO1 CA34233

Lymphoma Program Project Grant

Principal Investigator:  
Entire Period of Support:

Saul Rosenberg, M.D.  
04/01/83 - 03/31/86

Project 7A: Immunologic and Genetic Phenotyping of Human Lymphomas and Related Leukemias

Project Investigators:  
Percent Effort:

Roger Warnke and Michael Link  
5%

Project 3A: Clinical Investigations of Pediatric Hodgkin's Disease

Project Investigator:  
Percent Effort:

Sarah Donaldson  
5%

NIH P01 CA34233

Lymphoma Program Project Grant

Principal Investigator:  
Entire Period of Support:

Saul Rosenberg, M.D.  
04/01/86 - 03/31/91

Project 1B: Clinical Investigations of Pediatric Hodgkin's Disease

Project Investigator:  
Percent Effort:

Sarah Donaldson  
2%

Core Bii: Immunophenotyping of Lymphomas and Related Leukemias

Project Co-Directors:  
Percent Effort:

Roger Warnke and Michael Link  
5%

NIH U10 CA30969

Pediatric Oncology Group  
Sarcoma Committee Chairman

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Michael P. Link, M.D.  
04/1/91 - 12/31/93  
10%

NIH U10 CA30969

Pediatric Oncology Group  
Reference Laboratory

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Michael P. Link, M.D.  
04/1/91 - 12/31/94  
3%

NIH U10 CA24507

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Intergroup Rhabdomyosarcoma Study

Harold Maurer, M.D.  
1/1/89-12/31/94  
5%

NIH PO1 CA34233

Principal Investigator:  
Entire Period of Support:

Lymphoma Program Project Grant

Ron Levy, M.D.  
4/1/91 - 3/31/95

Core Bii: Pathology Core:

Diagnosis, Tissue Distribution,  
Immunophenotyping, Cytogenetics

NIH U10 CA33603

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Pediatric Oncology Group

Michael P. Link, M.D.  
04/1/91 - 12/31/95  
20%

NIH U10 CA30969

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Pediatric Oncology Group  
Vice Chairman

Sharon Murphy, M.D.  
01/1/94 - 12/31/95  
10%

NIH RO1 CA56060

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Clinical Investigations of  
Hodgkin's Disease

Sandra Horning, M.D.  
2/01/92 - 1/31/97  
4%

NIH U10 CA24507

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Intergroup Rhabdomyosarcoma Study

Harold Maurer, M.D.  
1/1/95-12/31/96  
5%

American Cancer Society IRG-32-36

Principal Investigator  
Entire Period of Support

Institutional Research Grant

Michael P. Link, M.D.  
7/1/95 - 6/30/98

NIH U01 CA55727

Childhood Cancer Survivor Study

Program Director:  
Principal Investigator:  
Entire Period of Support:  
Percent Effort

Leslie L. Robison, Ph.D.  
Michael P. Link, M.D.  
6/1/93 - 11/30/98  
5%

NIH U10 CA30969

Pediatric Oncology Group  
Vice Chairman

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Sharon Murphy, M.D.  
1/1/96 - 12/31/2000  
15%

NIH U10 CA33603

Pediatric Oncology Group

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Michael P. Link, M.D.  
1/1/96 - 12/31/2000  
23%

NIH U10 CA24507

Intergroup Rhabdomyosarcoma Study

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

William Crist, M.D.  
1/1/97-12/31/2000  
5%

NIH U10 CA30969

Pediatric Oncology Group  
ALL Cell Bank Chairman

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

Sharon Murphy, M.D.  
1/1/96 - 12/31/2001  
5%

Electric Power Research Institute (EPRI) RF2964-13

Childhood Leukemia: Role of electric  
and magnetic field exposure (EMF)  
in relapse and survival

Principal Investigator:  
Entire Period of Support:  
Percent Effort:

\_\_\_\_\_ M.D., MPH  
11/1/95-12/31/2001  
6%

NIH U10 CA33603

Children's Oncology Group

Principal Investigator  
Entire Period of Support:  
Percent Effort:

Michael P. Link, MD  
1/1/01 - 12/31/2002  
23%

NIH U10 CA30969

Children's Oncology Group  
Associate Chairman

Principal Investigator  
Entire Period of Support:  
Percent Effort:

Greg Reaman  
7/1/01 - 12/31/2002  
15%

NIH U10 CA30969

Children's Oncology Group  
Chairman, Data and Safety Monitoring  
Committee for Solid Tumors

Principal Investigator  
Entire Period of Support:  
Percent Effort:

Greg Reaman  
7/1/01 - 12/31/2002  
5%

**CURRENT GRANT SUPPORT:**

NIH U10 CA98543

Children's Oncology Group  
Associate Chairman

Principal Investigator  
Entire Period of Support:  
Percent Effort:

Greg Reaman  
3/1/03 - 2/28/2004  
15%

NIH U10 CA98543

Children's Oncology Group  
Institutional Principal Investigator

Principal Investigator  
Entire Period of Support:  
Percent Effort:

Greg Reaman  
3/1/03 - 2/28/04  
15%

## ORIGINAL ARTICLES

1. **Link MP** and Alter BP: Fetal erythropoiesis in transient erythroblastopenia of childhood. *Pediatr Res* 15:1036-1039, 1981.
2. Jaffe N, **Link MP**, Cohen D, Traggis D, Frei E, Watts H, Beardsley GP and Abelson HT: High dose methotrexate in osteogenic sarcoma. *National Cancer Institute Monograph* 56:201-206, 1981.
3. Jaffe N, Goorin A, **Link MP**, Watts H, Frei E, Vawter G, Fellows KE, Beardsley GP and Abelson HT: High dose methotrexate in osteogenic sarcoma adjuvant chemotherapy and limb salvage results. *Cancer Treat Rep* 65 (Suppl 1): 99-106, 1981.
4. Abelson HT, Fosburg MT, Beardsley GP, Goorin AM, Gorka C, **Link M** and Link D. Methotrexate-induced renal impairment: Clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. *J Clin Oncol* 1:208-216, 1983.
5. **Link MP**, Roper M, Dorfman RF, Crist WM, Cooper MD and Levy R: Cutaneous lymphoblastic lymphoma with pre-B markers. *Blood* 61:838-841, 1983.
6. **Link MP**, Warnke R, Finlay JL, Amylon MD, Miller RA, Dilley J and Levy R: A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies. *Blood* 62:722-728, 1983.
7. Paryani SB, Donaldson SS, Amylon MD and **Link MP**. Cranial nerve involvement in children with leukemia and lymphoma. *J Clin Oncol* 1:542-545, 1983.
8. Constine LS, Donaldson SS, McDougall IR, Cox RS, **Link MP** and Kaplan HS. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. *Cancer* 53:878-883, 1984.
9. Goorin A, Delorey M, Lack E, Gelber R, Price K, Cassady J, Levey R, Tapper D, Jaffe N, **Link M** and Abelson HT. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: Analysis of 32 patients. *J Clin Oncol* 2:425-431, 1984.
10. **Link MP**, Donaldson SS, Kempson R, Wilbur JR and Glader BE. Acute nonlymphocytic leukemia developing during the course of Ewing's sarcoma. *Med Pediatr Oncol* 12:194-200, 1984.
11. Wood GS, **Link MP**, Warnke RA, Dilley J and Levy R. Panleukocyte monoclonal antibody L3B12: Characterization and application to research and diagnostic problems. *Am J Clin Pathol* 81:176-183, 1984.

12. Amylon MD, **Link MP**, Glader BE. Immune thrombocytopenia associated with acute non-lymphocytic leukemia (ANLL). *J Pediatr* 105:776-778, 1984.
13. Smith SD, Shatsky M, Cohen PS, Warnke R, **Link MP** and Glader BE. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. *Cancer Res* 44:5657-5660, 1984.
14. Meeker TC, Miller RA, **Link MP**, Bindl J, Warnke R and Levy R. A unique human B lymphocyte antigen defined by a monoclonal antibody. *Hybridoma* 3:305-320, 1984.
15. Greenberg PL, Baker S, **Link M**, Minowada J. Immunologic selection of hemopoietic precursor cells utilizing antibody-mediated plate binding ("panning"). *Blood* 65:190-197, 1985.
16. Carroll WL, Kempson RL, Goven DE, Freiha FS, Shochat SJ, **Link MP**. Conservative management of testicular endodermal sinus tumor in childhood. *J Urology* 133:1011-1014, 1985.
17. Crist WM, Cleary ML, Grossi CE, Prasthofer EF, Heggie GD, Omura GA, Carroll AJ, **Link MP**, Sklar J. Acute leukemias associated with the 4;11 chromosome translocation have rearranged immunoglobulin heavy chain genes. *Blood* 66:33-38, 1985.
18. **Link MP**, Stewart SJ, Warnke RA and Levy R. Discordance between surface and cytoplasmic expression of the Leu 4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies. *J Clin Invest* 76:248-253, 1985.
19. Morgan R, Hecht F, Cleary M, Sklar J, and **Link M**. Leukemia with Down's Syndrome: Translocation between chromosomes 1 and 19 in acute myelomonocytic leukemia following transient congenital myeloproliferative syndrome. *Blood* 66:1466-1468, 1985.
20. Weiss LM, Bindl J, Picozzi VJ, **Link MP**, and Warnke RA. Lymphoblastic lymphoma: An immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia (ALL). *Blood* 67:474-478, 1986.
21. Bunin NJ, Hvizdala E, **Link M**, Callihan TR, Hustu HO, Wharam M, Warnke RA, Berard CW and Murphy SB. Mediastinal non-lymphoblastic lymphomas in children: A clinicopathologic study. *J Clin Oncol* 4:154-159, 1986.
22. Smith SD, Morgan R, **Link MP**, McFall P, Hecht F. Cytogenetic and immunophenotypic analysis of cell lines established from patients with T-cell leukemia/lymphoma. *Blood* 67:650-656, 1986.

23. Goorin AM, Delorey M, Gelber RD, Price K, Vawter G, Jaffe N, Watts H, **Link M**, Frei E, and Abelson HT. The Dana-Farber Cancer Institute/The Children's Hospital adjuvant chemotherapy trials for osteosarcoma: Three sequential studies. *Cancer Treat Symposia* 3:155-159, 1986.
24. Hecht F, Hecht BK, Morgan R, Sandberg AA and **Link MP**. Chromosome clues to acute leukemia in Down's syndrome. *Cancer Genet Cytogenet* 21:93-98, 1986.
25. Finlay J, Luft B, Yousem S, Wood G, **Link M**, Arvin A, Glader B, Lennette E, Shatsky M, Olds L, Borchering W, Hong R, and Purtle D. Chronic infectious mononucleosis syndrome, pancytopenia and polyclonal B-lymphoproliferation terminating in acute lymphoblastic leukemia. *Am J Pediatr Hematol/Oncol* 8:18-27, 1986.
26. **Link MP**, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, Ayala AG, Shuster JJ, Abelson HT, Simone JV, and Vietti TJ. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. *N Engl J Med* 314:1600-1606, 1986.
27. Denny CT, Hollis GF, Hecht F, Morgan R, **Link MP**, Smith SD and Kirsch IR. A common mechanism of chromosomal inversion in B and T cell tumors: Relevance to lymphocyte development. *Science* 234:197-200, 1986.
28. **Link MP**, Bindl J, Meeker TC, Carswell C, Doss CA, Warnke RA and Levy R. A unique antigen on mature B cells defined by a monoclonal antibody. *J Immunol* 137:3013-3018, 1986.
29. Smith SD, Morgan RD, Galili N, Amylon MD, **Link M**, Hecht F, Sklar J and Glader BE. Establishment and characterization of a common acute lymphoblastic leukemia cell line with a deletion of chromosome 3 band q26. *Cancer Res* 47:1652-1656, 1987.
30. Linker CA, Levitt LJ, O'Donnell M, Ries CA, **Link MP**, Forman SJ and Farbstein MJ. Improved results of treatment of adult acute lymphoblastic leukemia. *Blood* 69:1242-1248, 1987.
31. Donaldson SS and **Link MP**. Combined modality treatment with low dose radiation and MOPP chemotherapy for children with Hodgkin's disease. *J Clin Oncol* 5:742-749, 1987.
32. Garcia CF, Weiss LM, Lowder J, Komoroske C, **Link MP**, Levy R, and Warnke RA. Quantitation and estimation of lymphocyte subsets in tissue sections: Comparison with flow cytometry. *Am J Clin Path* 87:470-477, 1987.
33. Grier HE, Gelber RD, Camitta BM, Delorey MJ, **Link MP**, Price K, Weinstein HJ. Prognostic factors in childhood acute myelogenous leukemia. *J Clin Oncol* 5:1026-1032, 1987.



34. Goorin AM, Perez-Atayde A, Gebhardt M, Andersen JW, Wilkinson RH, Delorey MJ, Watts H, **Link M**, Jaffe N, Frei E and Abelson HT. Weekly high dose methotrexate and doxorubicin for osteosarcoma: The Dana-Farber Cancer Institute/The Children's Hospital Study III. *J Clin Oncol* 5:1178-1184, 1987.
35. Clayberger C, Wright A, Medeiros LJ, Koller TD, **Link MP**, Smith SD, Warnke RA and Krensky AM. Absence of cell surface LFA-1 as a mechanism of escape from immune surveillance. *Lancet* 2:533-536, 1987.
36. Weintrub PS, Sullender WM, Lombard C, **Link MP**, and Arvin A. Giant cell pneumonia caused by parainfluenza type 3 in a patient with acute myelomonocytic leukemia. *Arch Pathol Lab Med* 111:569-570, 1987.
37. Smith SD, Morgan R, Gemmell R, Amylon MD, **Link MP**, Hecht BK, Warnke R, Glader BE and Hecht F. Clinical and biologic characterization of T cell neoplasias with rearrangements of chromosome 7 band q34. *Blood* 71:395-402, 1988.
38. Carroll WL, **Link MP**, Cleary MD, Bologna S, Carswell C, Amylon MD, Smith SD and Levy R. Idiotype as a tumor-specific marker in childhood B cell acute lymphoblastic leukemia. *Blood* 71:1068-1073, 1988.
39. Naumovski L, Morgan R, Hecht F, **Link MP**, Glader BE and Smith SD. Philadelphia chromosome positive acute lymphoblastic leukemia cell lines without classic bcr rearrangement. *Cancer Res* 48:2876-2879, 1988.
40. Bird J, Galili N, **Link M**, Stites D and Sklar J. Continuing rearrangement but absence of somatic hypermutation in immunoglobulin genes of human B cell precursor leukemia. *J Exp Med* 168:229-245, 1988.
41. Miller L, **Link MP**, Bologna S and Parker BR. Cerebellar atrophy caused by high-dose cytosine arabinoside: CT and MR findings. *AJR* 152:343-344, 1989.
42. Finlay JL, Trigg ME, **Link MP** and Frierdich S. Poor risk nonlymphoblastic lymphoma of childhood: Results of an intensive pilot study. *Med Pediatr Oncol* 17:29-38, 1989.
43. Mefferd JM, Donaldson SS, **Link MP**. Pediatric Hodgkin's disease: Pulmonary, cardiac and thyroid function following combined modality therapy. *Int J Radiat Biol Phys* 16:679-685, 1989.
44. Smith SD, McFall P, Morgan R, **Link M**, Hecht F, Cleary M and Sklar J. Long-term growth of malignant thymocytes in vitro. *Blood* 73:2182-2187, 1989.

45. Wright A, Lee JE, **Link MP**, Smith SD, Carroll W, Levy R, Clayberger C, and Krensky AM. Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor delta chain. *J Exp Med* 169:1557-1564, 1989.
46. Hutchinson RE, Murphy SB, Fairclough D, Shuster JJ, Sullivan M, **Link M**, Donaldson SS and Berard CW. Diffuse small noncleaved cell lymphoma in children, Burkitt's versus non-Burkitt's types: Results from the Pediatric Oncology Group and St. Jude Children's Research Hospital. *Cancer* 64:23-28, 1989.
47. Carroll WL, Yu M, **Link MP** and Korsmeyer SJ. Absence of immunoglobulin variable region gene somatic hypermutation in advanced Burkitt's lymphoma. *J Immunol* 143:692-698, 1989.
48. Smith LM, Donaldson SS, Egbert PR, **Link MP** and Bagshaw MA. Aggressive management of second primary tumors in survivors of hereditary retinoblastoma. *Int J Radiat Biol Phys* 17:499-505, 1989.
49. Ayala AG, Ro JY, Raymond AK, Jaffe N, Chawla S, Carrasco H, **Link M**, Jimenez J, Edeiken J, Wallace S, Murray JA, Benjamin R. Small cell osteosarcoma: A clinicopathologic study of 27 cases. *Cancer* 64:2162-2173, 1989.
50. Tycko B, Palmer JD, **Link MP**, Smith SD, Sklar J. Polymerase chain reaction amplification of rearranged antigen receptor genes using junction-specific oligonucleotides: Possible application for detection of minimal residual disease in acute lymphoblastic leukemia. *Cancer Cells* 7:47-52, 1989
51. **Link MP**, Donaldson SS, Berard CW, Shuster JJ and Murphy SB. Results of treatment of childhood localized non-Hodgkin's Lymphoma with combination chemotherapy with or without radiotherapy. *N Engl J Med* 322:1169-1174, 1990.
52. Donaldson SS, Whitaker SJ, Plowman PN, **Link MP** and Malpas JS. Stage I-II Pediatric Hodgkin's disease: Long-term follow-up demonstrates equivalent survival rates following different management schemes. *J Clin Oncol* 8:1128-1137, 1990.
53. Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, Behm F, **Link M**, Steuber P, Ragab A, Hirt A, Brock B, Land V, Pullen J. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group Study. *Blood* 76:489-494, 1990.
54. Pui C-H, Carroll AJ, Head D, Raimondi SC, Shuster JJ, Crist WM, **Link MP**, Borowitz MJ, Behm FG, Land VJ, Nash MB, Pullen DJ, and Look AT. Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood. *Blood* 76:590-596, 1990.

55. Carroll A, Crist W, Link M, Amylon M, Pullen J, Ragab A, Buchanan G, Vietti T. The t(1;14)(p34;q11) is non-random and restricted to T-cell acute lymphoblastic leukemia. A Pediatric Oncology Group Study. *Blood*, 76:1220-1224, 1990.
56. Venturelli D, Mariano MT, Szczylik C, Valtieri M, Lange B, Crist W, Link M and Calabretta B. Down-regulated *c-myb* expression inhibits DNA synthesis of T-leukemia cells in most patients. *Cancer Res*, 50:7371-7375, 1990.
57. Suryanarayan K, Hunger SP, Kohler S, Carroll AJ, Crist W, Link MP and Cleary ML. Consistent involvement of the *bcr* gene by 9;22 breakpoints in pediatric acute leukemias. *Blood* 77:324-330, 1991.
58. Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S, and Arvin A. Lack of transmission of the live attenuated Varicella vaccine virus to immunocompromised children after immunization of their siblings. *Pediatrics* 87:166-170, 1991.
59. Hunger SP, Galili N, Carroll AJ, Crist WM, Link, MP, and Cleary ML. The t(1;19)(q23;p13) results in consistent fusion of *E2A* and *PBX1* coding sequences in acute lymphoblastic leukemias. *Blood* 77:687-693, 1991.
60. Russo C, Carroll A, Kohler S, Borowitz M, Amylon M, Homans A, Kedar A, Shuster J, Land V, Crist W, Pullen J, and Link M. The Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group Study. *Blood* 77:1050-1056, 1991.
61. Goorin AM, Shuster JJ, Baker A, Horowitz M, Meyer WH, Link MP. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: Results from the Multi-Institutional Osteosarcoma Study. *J Clin Oncol* 9:600-605, 1991.
62. Krischer JP, Ragab AH, Kun L, Kim TH, Laurent JP, Boyett JM, Cornell CJ, Link M, Luthy AR, and Camitta B. Nitrogen mustard, vincristine, procarbazine and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma: A Pediatric Oncology Group Study. *J Neurosurg* 74:905-909, 1991.
63. Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J. Adjuvant chemotherapy of high grade osteosarcoma of the extremity: Updated results of the Multi-Institutional Osteosarcoma Study. *Clin Orthop* 270:8-14, 1991.
64. Hunger SP, Sklar J, and Link MP. Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: Report of three cases and review of the literature. *J Clin Oncol* 10:156-163, 1992.
65. Watson MS, Land VJ, Carroll AJ, Pullen J, Borowitz M, Link MP, Amylon M, and Behm FG. t(2;14)(p13;q32): A recurring abnormality in lymphocytic leukemia. A Pediatric Oncology Group Study. *Cancer Genetics and Cytogenetics* 58:121-124, 1992.

66. Vietti TJ, Land V, Shuster JJ, Amylon MA, **Link M**, Berard C, Crist W, Borowitz M, Falletta J, Bowman WP, Brecher M, Castleberry R, Frankel L, Goorin A, Hayes FA, Hvizdala E, Krischer JP, Pollock BH, McWilliams N, Murphy S, Pick T, Pullen J, Ravindranath Y, Smith EI, Steuber CP, Sullivan M, van Eys, J, Wharam M, . Progress Against Childhood Cancer: The Pediatric Oncology Group Experience. *Pediatrics* 89:597-600, 1992.
67. Pui C-H, Carroll AJ, Raimondi SC, Schell MJ, Head DR, Shuster JJ, Crist WM, Borowitz MJ, **Link MP**, Behm FG, Steuber CP and Land VJ. Isochromosomes in childhood acute lymphoblastic leukemia: A collaborative study of 83 cases. *Blood* 79:2384-2391, 1992.
68. Ribeiro RC, Pui C-H, Murphy SB, Shuster JJ, Hvizdala EV, Falletta J, **Link MP**, Sullivan MP, Pick TE, Sandlund J, Fairclough D, Crist WM, Berard, CW. Childhood malignant non-Hodgkin's lymphomas of uncommon histology. *Leukemia* 6:761-765, 1992.
69. Crist W, Shuster J, Look T, Borowitz M, Behm F, Bowman P, Frankel L, Pullen J, Krance R, Steuber P, Cammitta B, Amylon M, **Link M**, and Land V. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. *Leukemia* 6 (Suppl 2): 162-167, 1992.
70. Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D, Behm F, Crist WM, **Link M**, Borowitz M, and Pullen DJ. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group Study. *Leukemia* 6:357-362, 1992.
71. Vats T, Buchanan G, Mehta P, Ragab A, Hvizdala E, Nitschke R, **Link M**, Beardsley GP, Maybee D, Krischer J. A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse: A Pediatric Oncology Group study. *Invest New Drugs* 10:231-234, 1992.
72. Morrissey J, Tkachuk DC, Milatovich A, Francke U, **Link M**, and Cleary ML. A serine/proline-rich protein is fused to HRX in t(4;11) acute leukemias. *Blood* 81:1124-1131, 1993.
73. Bash RO, Crist WM, Shuster JJ, **Link, MP**, Amylon M, Pullen J, Carroll AJ, Buchanan GR, Smith RG, and Baer R. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the *TAL1* locus: A Pediatric Oncology Group Study. *Blood* 81:2110-2117, 1993.
74. Hudson MM, Weinstein HJ, Donaldson SS, Greenwald C, Kun L, Tarbell NJ, Humphrey WA, Rupp C, Marina NM, Wilimas J, and **Link MP**. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. *J Clin Oncol* 11:1080-1084, 1993.

75. **Link MP**, Stevens J, Friend SH, Israel MA, Knudson AG, and Sondel PM. Laboratory-clinical interface. *Cancer* 71(suppl):3219-3221, 1993.
76. Hunger SP, Tkachuk DC, Amylon MD, **Link MP**, Carroll AJ, Welborn JL, Willman CL, and Cleary ML. *HRX* involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. *Blood* 81:3197-3203, 1993.
77. Mogul M, Hartman G, Donaldson S, Gelb A, **Link M**, Amylon M, and Glader B. Langerhans' cell histiocytosis presenting with the superior vena cava syndrome: A case report. *Med Pediatr Oncol* 21:456-459, 1993.
78. Ramani P, Rampling D, and **Link M**. Immunocytochemical study of 12E7 in small round cell tumours of childhood: an assessment of its sensitivity and specificity. *Histopathology* 23:557-561, 1993.
79. Downing JR, Head DR, Parham DM, Douglass EC, Hulshof MG, **Link MP**, Motroni TA, Grier HE, Curcio-Brint AM, and Shapiro DN. Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction. *Am J Path* 143:1294-1300, 1993.
80. Cleary SF, **Link, MP**, and Donaldson SS. Hodgkin's disease in the very young: *Int J Radiat Biol Phys* 28:77-83, 1994.
81. Perlman EJ, Dickman PS, Askin FB, Grier HE, Miser JS, and **Link MP**. Ewing's sarcoma--Routine diagnostic utilization of MIC-2 analysis: A Pediatric Oncology Group/Children's Cancer Group intergroup study. *Human Pathology* 25:304-307, 1994.
82. Rubnitz JE, **Link MP**, Shuster JJ, Carroll AJ, Hakami N, Frankel LS, Pullen DJ, and Cleary ML. Frequency and prognostic significance of *HRX* rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group study. *Blood* 84:570-573, 1994.
83. Russo CL, McIntyre J, Goorin AM, **Link MP**, Gebhardt MC, and Friend SH. Secondary breast cancer in patients presenting with osteosarcoma: Possible involvement of germline p53 mutations. *Med Pediatr Oncol* 23:354-358, 1994.
84. Fizzotti M, Chen EY, **Link MP**, Carroll AJ, Foroni L, Rabbitts TH, Crist WM and Clark SS. Simultaneous expression of *RBTN-2* and *BCR-ABL* oncogenes in a T-ALL with a t(11;14)(p13;q11) and a late appearing Philadelphia chromosome. *Leukemia* 8:1124-1130, 1994.
85. Jacknow DS, Tschann JM, **Link MP**, and Boyce WT. Hypnosis in the prevention of chemotherapy-related nausea and vomiting in children: A prospective study. *J Dev Behav Pediatr* 15:258-264, 1994.

86. Hunger SP, **Link MP**, and Donaldson SS. ABVD/MOPP and low dose involved-field radiotherapy in pediatric Hodgkin's Disease: The Stanford experience. *J Clin Oncol* 12:2160-2166, 1994.
87. Riopel M, Dickman PS, **Link MP**, and Perlman EJ. MIC2 analysis in pediatric lymphomas and leukemias. *Hum Pathol* 25:396-399, 1994.
88. Pettenati MJ, Rao N, Wofford M, Shuster JJ, Pullen DJ, **Link MP**, Steuber CP, and Carroll AJ. Presenting characteristics of trisomy 8 as the primary cytogenetic abnormality associated with childhood acute lymphoblastic leukemia. *Cancer Genet Cytogenet* 75:6-10, 1994.
89. Harris MB, Cantor AB, Goorin AM, Shochat SJ, Ayala AG, Ferguson WS, Holbrook T, and **Link MP**. Treatment of osteosarcoma with Ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A Pediatric Oncology Group study. *Med Pediatr Oncol* 24:87-92, 1995.
90. Goorin A, Strother D, Poplack D, Letvak L, George M and **Link M**. The safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma. *Med Pediatr Oncol* 24:362-367, 1995.
91. Hutchison RE, Berard CW, Shuster JJ, **Link MP**, Pick TE, and Murphy SB. B-cell lineage confers a favorable outcome among children and adolescents with large cell lymphoma: A Pediatric Oncology Group study. *J Clin Oncol* 13:2023-2032, 1995.
92. Lawrence HJ, Sauvageau G, Ahmadi N, Lopez AR, LeBeau MM, **Link M**, Humphries K, and Largman C. Stage- and lineage-specific expression of the *HOXA10* homeobox gene in normal and leukemic hematopoietic cells. *Experimental Hematology* 23:1160-1166, 1995.
93. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, **Link M**, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, and Ungerleider R. Uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia. *J Clin Oncol* 14:18-24, 1996.
94. Marks DI, Kurz BW, **Link MP**, Ng E, Shuster JJ, Lauer SJ, Brodsky I, Haines DS. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. *Blood* 87:1155-1161, 1996.
95. Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, **Link M**, Head D, Carroll A, Berard C, and Murphy S. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: A Pediatric Oncology Group study (8617). *J Clin Oncol* 14:1252-1261, 1996.

96. Rubnitz JE, Shuster JJ, Land VJ, **Link MP**, Pullen DJ, Camitta BM, Pui C-H, Downing JR and Behm FG. Case-control study suggests a favorable impact of *TEL* rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: A Pediatric Oncology Group study. *Blood* 89:1143-1146, 1997.
97. Marks DI, Kurz BW, **Link MP**, Ng E, Shuster JJ, Lauer SJ, Carroll D, Brodsky I, Haines DS. Altered expression of p53 and *mdm-2* proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. *J Clin Oncol* 15:1158-1162, 1997.
98. Batova A, Diccianni MB, Yu JC, Nobori T, **Link MP**, Pullen J, and Yu AL. Frequent and selective methylation of *p15* and deletion of both *p15* and *p16* in T-cell acute lymphoblastic leukemia. *Cancer Research* 57:832-836, 1997.
99. Arndt C, Tefft M, Gehan E, Anderson J, Jenson M, **Link M**, Donaldson S, Breneman J, Wiener E, Weber B, Maurer H. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. *J Pediatr Hematol/Oncol* 19:124-129, 1997.
100. Hutchison RE, Banki K, Shuster JJ, Barrett D, Dieck C, Berard CW, Murphy SB, **Link MP**, Pick TE, Laver J, Schwenn M, Mathew P, Morris SW. Use of an anti-ALK antibody in the characterization of anaplastic large cell lymphoma of childhood. *Ann Oncol* 8(suppl 1):37-42, 1997.
101. Maloney KW, Rubnitz JE, Cleary ML, Frankel LS, Hakami N, **Link MP**, Pullen DJ, and Hunger SP. Lack of *ETV6 (TEL)* gene rearrangements or *p16<sup>INK-4A</sup>/p15<sup>INK-4B</sup>* homozygous gene deletions in infant acute lymphoblastic leukemia. *Leukemia* 11:979-983, 1997.
102. **Link MP**, Shuster JJ, Donaldson SS, Berard CW, and Murphy SB. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. *N Engl J Med* 337:1259-1266, 1997.
103. Brecher ML, Schwenn MR, Coppes MJ, Bowman WP, **Link MP**, Berard CW, Shuster JJ, and Murphy SB. Fractionated cyclophosphamide and back to back high dose methotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small non-cleaved cell lymphomas (SNCCCL): A randomized trial of the Pediatric Oncology Group. *Med Pediatr Oncol* 29:526-533, 1997.
104. Hunger SP, Fall MZ, Camitta BM, Carroll AJ, **Link MP**, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Steuber CP, and Cleary ML. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): A Pediatric Oncology Group study. *Blood* 91:1021-1028, 1998.

105. Laver J, Amylon M, Desai S, **Link M**, Schwenn M, Mahmoud H, and Shuster J. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: A Pediatric Oncology Group Pilot Study. *J Clin Oncol* 16:522-526, 1998.
106. Donaldson SS, Torrey M, **Link MP**, Glicksman A, Gilula L, Laurie F, Manning J, Neff J, Reinus W, Thompson E, Shuster JJ. A multi-disciplinary study investigating radiotherapy in Ewing's sarcoma: End results of POG #8346. *Int J Radiat Oncol Biol Phys* 42:125-135, 1998.
107. Harris MB, Gieser P, Goorin AM, Ayala A, Shochat SJ, Ferguson WS, Holbrook T, and **Link MP**. Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group study. *J Clin Oncol* 16:3641-3648, 1998.
108. Rubnitz JE, Camitta BM, Mahmoud H, Raimondi SC, Carroll AJ, Borowitz MJ, Shuster JJ, **Link MP**, Pullen DJ, Downing JR, Behm FG, Pui C-H. Heterogeneity of the t(11;19)(q23;p13) in childhood acute lymphoblastic leukemia: Favorable prognosis with T-cell phenotype. *J Clin Oncol* 17:191-196, 1999.
109. Amylon MD, Shuster J, Pullen J, Berard C, **Link MP**, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB. Intensive high dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. *Leukemia* 13:335-342, 1999.
110. Suryanarayan K, Shuster JJ, Donaldson SS, Hutchison RE, Murphy SB, **Link MP**. Treatment of localized primary non-Hodgkin's lymphoma of bone in children: A Pediatric Oncology Group Study. *J Clin Oncol* 17:456-459, 1999.
111. Navid, F, Mosijczuk AD, Head DR, Borowitz MJ, Carroll AJ, Brandt JM, **Link MP**, Rozans, MK, Thomas GA, Schwenn MR, Shields DJ, Vietti, TJ, Pullen DJ. Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group experience. *Leukemia* 13:135-141, 1999.
112. Pullen J, Shuster JJ, **Link M**, Borowitz M, Amylon M, Carroll AJ, Land V, Look AT, McIntyre B, Camitta B. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. *Leukemia* 13:1696-1707, 1999.
113. Hutchison RE, Finch C, Kepner J, Fuller C, Bowman P, **Link M**, Schwenn M, Laver J, Desai S, Barrett D, Murphy SB. Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons. *Annals of Oncology* 11(suppl. 1):S35-S38, 2000.



114. Baker KS, Anderson JR, **Link MP**, Grier HE, Qualman SJ, Maurer HM, Breneman JC, Wiener ES, Crist WM. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: Results from the Intergroup Rhabdomyosarcoma Study IV. *J Clin Oncol* 18:2427-2434, 2000.
115. Schneider NR, Carroll AJ, Shuster JJ, Pullen DJ, **Link MP**, Borowitz MJ, Camitta BM, Katz JA, Amylon MD. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia. A Pediatric Oncology Group report of 343 cases. *Blood* 96:2543-2549, 2000.
116. Laver JH, Barredo JC, Amylon M, Schwenn M, Kurtzberg J, Camitta BM, Pullen J, **Link MP**, Borowitz M, Ravindranath Y, Murphy SB, Shuster J. Effects of cranial radiation in children with high risk T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group report. *Leukemia* 14:369-373, 2000.
117. Hilden JM, Emanuel EJ, Fairclough DL, **Link MP**, Foley KM, Clarridge BC, Schnipper LE, Mayer RJ. Attitudes and practices among pediatric oncologists regarding end-of-life care: Results of the 1998 American Society of Clinical Oncology survey. *J Clin Oncol* 19:205-212, 2001.
118. Verneris M, McDougall IR, Becton D, **Link MP**. Thyroid carcinoma after successful treatment of osteosarcoma: A report of three patients. *J Pediatr Hematol/Oncol* 23:312-315, 2001.
119. Arndt CAS, Donaldson SS, Anderson JR, Andrassy RJ, Laurie F, **Link MP**, Raney RB, Maurer HM, Crist WM. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? *Cancer* 91:2454-2468, 2001.
120. Wiener ES, Anderson JR, Ojimba JI, Lobe TE, Paidas C, Andrassy RJ, Raney RB, Qualman SJ, Donaldson SS, Maurer HM, **Link MP**, Crist WM, Grier HE. Controversies in the management of paratesticular rhabdomyosarcoma: Is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? *Semin Pediatr Surg* 10:146-152, 2001.
121. Ferguson WS, Harris MB, Goorin AM, Gebhardt MC, **Link MP**, Shochat SJ, Siegel GP, Devidas M, Grier HE. Pre-surgical window of carboplatin and surgery and multi-drug chemotherapy for the treatment of newly-diagnosed metastatic or unresectable osteosarcoma: A Pediatric Oncology Group trial. *J Pediatr Hematol/Oncol* 23:340-348, 2001.
122. Sandler E, Lyden E, Ruyman F, Maurer H, Wharam M, Parham D, **Link M**, Crist W. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. *Med Pediatr Oncol* 37:442-448, 2001.

123. Smith LM, Anderson JR, Qualman SJ, Crist WM, Paidas CN, Teot LA, Pappo AS, **Link MP**, Grier HE, Wiener ES, Breneman JC, Raney RB, Maurer HM, Donaldson SS. Which patients with rhabdomyosarcoma (RMS) and microscopic residual tumor (group II) fail therapy? A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *J Clin Oncol* 19:4058-4064, 2001.
124. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas, M, Siegal GP, Gebhardt MC, Schwartz CL, **Link M**, Grier HE. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group trial. *J Clin Oncol* 20:426-433, 2002.
125. Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein M, **Link MP**. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: A Pediatric Oncology Group study. *Clin Cancer Res* 8:413-418, 2002.
126. Donaldson SS, Hudson MM, Lamborn KR, **Link MP**, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Tarbell NJ, Weinstein HJ. VAMP and low-dose involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: Results of a prospective clinical trial. *J Clin Oncol* 20:3081-3087, 2002.
127. Friedman AM, Hudson MM, Weinstein HJ, Donaldson SS, Kun L, Tarbell NJ, **Link MP**. Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose involved-field radiation. *J Clin Oncol* 20:3088-3094, 2002.
128. Shuster J, **Link M**, Camitta B, Pullen J, Behm F. Minimax two-stage-designs with applications to tissue banking case-control studies. *Statist Med* 21:2479-2493, 2002.
129. Winter SS, Sweatman J, Shuster JJ, **Link MP**, Amylon MD, Pullen J, Camitta BM, Larson RS. Bone marrow stroma-supported culture of T-lineage acute lymphoblastic leukemia cells predicts treatment outcome in children: A Pediatric Oncology Group study. *Leukemia* 16:1121-1126, 2002.
130. Baker KS, Anderson JR, Lobe TE, Wharam MD, Qualman SJ, Raney RB, Ruymann FB, Womer RB, Meyer WH, **Link MP**, Crist WM. Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. *J Clin Oncol* 20:4428-4433, 2002.
131. Breneman JC, Lyden E, Pappo AS, **Link MP**, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma – A report from the Intergroup Rhabdomyosarcoma Study IV. *J Clin Oncol* 21:78-84, 2003.

132. Grier HE, Krailo MD, Tarbell NJ, **Link MP**, Fryer CJH, Pritchard DJ, Gebhardt MC, Dickman PS, Pearlman EJ, Meyers PA, Donaldson SS, Miser JS, Moore S, Rausen A, Vietti TJ,. Addition of ifosfamide and etoposide to standard chemotherapy in Ewing sarcoma/primitive neuroectodermal tumor of bone: A Children's Cancer Group/Pediatric Oncology Group Study. *N Engl J Med* 348:694-701, 2003.
133. Goorin AM, Schwartzenuber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, **Link MP**. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for non-metastatic osteosarcoma: Pediatric Oncology Group study POG-8651. *J Clin Oncol* 21:1574-1580, 2003.
134. Smith RS, Chen Q, Hudson MM, **Link MP**, Kun L, Weinstein H, Billett A, Marcus KJ, Tarbell NJ, Donaldson SS. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. *J Clin Oncol* 21:2026-2033, 2003.
135. Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, **Link MP**, Daw NC. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. *Cancer* 100:1724-1733, 2004.
136. Miser JS, Krailo MD, Tarbell NJ, **Link MP**, Fryer CJH, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Grier HE. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: Evaluation of combination ifosfamide and etoposide—A Children's Cancer Group and Pediatric Oncology Group study. *J Clin Oncol* 22:2873-2876, 2004.
137. Spunt SL, Smith LM, Ruyman FB, Qualman SJ, Donaldson SS, Rodeberg DA, Anderson JR, Crist WM, **Link MP**. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Clinical Cancer Research* 10:6072-6079, 2004.
138. Lieskovsky YYE, Donaldson SS, Torres MA, Wong RM, Amylon MD, **Link MP**, Agarwal R. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: Results and prognostic indices. *J Clin Oncol* 22:4532-4540, 2004.
139. Hudson MM, Krasin M, **Link MP**, Donaldson SS, Billups C, Merchant TE, Kun L, Billet AL, Kaste S, Tarbell NJ, Howard S, Friedmann AM, Hurwitz CA, Young JA, Marcus KC, Rai S, Cowan T, Weinstein HJ. Risk-adapted combined modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's lymphoma. *J Clin Oncol* 22:4541-4550, 2004.

140. George TI, Jeng M, Berquist W, Cherry AM, Link MP, Arber DA. Epstein-Barr virus-associated peripheral T-cell lymphoma and hemophagocytic syndrome arising after liver transplantation: Case report and review of the literature. *Pediatr Blood Cancer* 44:270-276, 2005.
141. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high dose methotrexate. *J Clin Oncol* 23:2004-2011, 2005.
142. Sayed K, Savell VH, Hutchison RE, Kepner J, Link MP, Schwenn M, Mahmoud H, Parham DM. Review of tonsillar lymphoma in pediatric patients from the Pediatric Oncology Group: What can be learned about some indications for microscopic examination? *Pediatr Dev Pathol* 8:533-40, 2005.
143. Bernstein ML, Devidas M, Lafreniere D, Souid A-K, Meyers PA, Gebhardt M, Stine K, Nicholas R, Perlman EJ, Dubowy R, Wainer IW, Dickman PS, Link MP, Goorin A, Grier HE. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group phase II study 9457--A report from the Children's Oncology Group. *J Clin Oncol* 24:152-159, 2006.
144. Foliart DE, Pollock BH, Mezei G, Iriye R, Silva JM, Ebi KL, Kheifets L, Link MP, Kavet R. Magnetic field exposure and long-term survival among children with leukaemia. *Br J Cancer* 94:161-164, 2006.

**APPEARS THIS WAY  
ON ORIGINAL**

**MANUSCRIPTS SUBMITTED FOR PUBLICATION**

1. Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, **Link MP**, Fryer CJH, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Grier HE. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing dose intensity of chemotherapy – A report from the Children’s Oncology Group. *Cancer*, submitted.
2. Merkel KD, Lowen N, Gebhardt MC, Shuster JJ, Goorin A, **Link M**. Long-term follow-up of patients undergoing limb salvage with post-operative multi-agent chemotherapy for grade IIB osteosarcoma of the extremities. *J Bone Joint Surg*, submitted.
3. Desai SJ, Amylon MD, Shuster JJ, Schwenn MR, Laver J, **Link MP**, Hutchison R, Buchanan G, Weitzman S, Camitta B, Murphy SB. Prognostic features in advanced stage (III-IV) non-Hodgkin’s Lymphoma: A Pediatric Oncology Group study. *Med Pediatr Oncol*, submitted.
4. Bhatia S, Krailo MD, Chen Z, Burden L, Dickman PS, Grier HE, **Link MP**, Meyers PA, Perlman EJ, Rausen AR, Robison LL, Vietti TJ, Miser JS. Therapy-related myelodysplasia and acute myeloid leukemia following Ewing sarcoma and primitive neuroectodermal tumor of bone. Submitted.
5. Foliart DE, Pollock BH, Mezei G, Iriye R, Silva JM, Ebi KL, Kheifets L, **Link MP**, Kavet R. Magnetic field exposure and prognostic factors in childhood leukaemia. *Br J Cancer*, submitted.

**APPEARS THIS WAY  
ON ORIGINAL**

## CHAPTERS AND MONOGRAPHS

1. Frei E, Jaffe N, **Link MP** and Abelson H: Adjuvant chemotherapy of osteogenic sarcoma: Progress, problems and prospects. In: Adjuvant Therapy of Cancer II. Proceedings of the International Conference on the Adjuvant Therapy of Cancer, Tucson, Arizona, USA 1979. (ed) SE Jones and SE Salmon, New York, Grune & Stratton. pp 355-363.
2. Weinstein HJ and **Link MP**: Childhood non-Hodgkin's lymphoma. Clinics in Hematology 8:699-716, 1979.
3. **Link MP**. Cancer in childhood. In: Physically Handicapped Children - A Medical Atlas for Teachers. (ed) EE Bleck and DA Nagel. New York, Grune & Stratton, 2nd Edition, 1982, p 43-58.
4. Miller RA, Stratte PT, Oseroff AR, **Link MP** and Levy R. Treatment of human T-cell lymphomas and leukemias with monoclonal anti-T cell antibodies. In: Hybridomas in Diagnosis and Treatment. ORTHO Pharmaceutical Ltd. (Canada) Symposium, 1982.
5. Levy R, Miller RA, Stratte PT, Maloney DG, **Link MP**, Meeker TC, Oseroff A, Thielemans K and Warnke R. Therapeutic trials of monoclonal antibody in leukemia and lymphoma: Biologic considerations. In: Monoclonal Antibodies and Cancer. Proceedings of the 4th Armand Hammer Cancer Symposium. (ed) RE Congrid, IS Trowbridge and R Dulbecco. Orlando Florida. Academic Press, 1983. pp 5-16.
6. Levy R, Stratte PT, **Link MP**, Oseroff A, Maloney DG and Miller RA: Monoclonal antibodies in leukemia therapy. In: Leukemia Research: Advances in Cell Biology and Treatment. (ed) S Murphy and J Gilbert. New York. Elsevier Science Publishing Co., Inc., 1983. p 269-279.
7. Warnke R and **Link M**. Identification and significance of cell markers in leukemia and lymphoma in node and marrow. Ann Rev Med 34:117-131, 1983.
8. Levy R, Stratte P, **Link M**, Maloney DG, Oseroff A and Miller RA. Monoclonal antibodies to human lymphocytes: Clinical application in the therapy of leukemia. In: Monoclonal Antibodies and Functional Cell Lines. (ed) RH Kennet, TJ McKearn and KB Bechtol. New York. Plenum Publishing Corp., 1984. pp 193-214.
9. Smith SD, Warnke RA, Shatsky M, **Link MP**, Cohen PS and Glader BE. Continuous in vitro growth of T-cell acute lymphoblastic leukemia of childhood (T-ALL) in an hypoxic environment. In: Human Tumor Cloning, (ed) SE Salmon and JM Trent. New York, Grune & Stratton Inc., 1984. pp 279-288.

10. Miller RA, Stratte P, Maloney DG, Oseroff A, **Link M** and Levy R. Therapeutic potential of monoclonal antibodies in leukemias and lymphomas. In: Quo Vadis? Flow Cytometry & Monoclonal Antibodies for Therapy Monitoring. (ed) P Gross, FK Jansen, P Poncelet, R Roncucci. Montpellier, France. Sanofi Recherche, 1984. pp 231-238.
11. **Link MP**. Non-Hodgkin's lymphoma in childhood. In: *Pediatr Clin North Am.* (ed) A Altman. Philadelphia, WB Saunders, Vol 32, 1985, pp 699-720.
12. Donaldson SS and **Link MP**. Childhood lymphomas: Hodgkin's disease and non-Hodgkin's lymphoma. In: *Comprehensive Textbook of Oncology.* (ed) SC Schimpff, MC Robson, and AR Moossa. Baltimore. Williams & Wilkins, 1986. pp 1161-1178.
13. **Link MP**. Osteosarcoma. In: *Comprehensive Textbook of Oncology.* (ed) SC Schimpff, MC Robson and AR Moossa. Baltimore. Williams & Wilkins, 1986. pp 1179-1190.
14. Amylon MD, **Link MP** and Murphy SB. Malignant T-cell and other non-Hodgkin's lymphoma. In: *Cancer in Children, Second Edition.* (ed) A. Barrett and PA Voute. London. Springer-Verlag, 1986. pp 152-163.
15. **Link MP**. Adjuvant chemotherapy of osteosarcoma. In: *Important Advances in Oncology 1986.* (ed) VT DeVita, S Hellman, SA Rosenberg. Philadelphia. J.P. Lippincott, 1986. pp 193-207.
16. **Link MP**. High dose methotrexate with leucovorin rescue in the treatment of osteosarcoma. In: *Folates & Antifolates in Cancer Chemotherapy: New Perspectives.* New York. World Health Communications, 1986. pp 1-13.
17. Weinstein H, Grier H, Gelber R, Camitta B, **Link M**, Delorey M, and Price K. Postremission induction intensive sequential chemotherapy for children with AML - Treatment results and prognostic factors. In: *Acute Leukemias. Haematology and Blood Transfusion 30:88-92.* (ed) T Buchner, G Schellong, W Hiddemann, D Urbanitz and J Ritter. Berlin, Germany. Springer Verlag, 1987.
18. **Link MP**, Shuster JJ, Goorin AM, Miser A, Meyer WH, Kingston JE, Belasco J, Baker AR, Ayala AG and Vietti T. Adjuvant chemotherapy in the treatment of osteosarcoma: Results of the Multi-Institutional Osteosarcoma Study. In: *Recent Concepts in Sarcoma Treatment. Proceedings of the International Symposium on Sarcomas, Tarpon Springs, Florida, October 8-10, 1987.* (ed) J Ryan and LO Baker. Dordrecht, The Netherlands, Kluwer Academic Publishers, 1988. pp 283-290.
19. Donaldson SS, **Link MP**, McDougall IR, Parker BR and Shochat SJ. Clinical investigations of children with Hodgkin's disease at Stanford University Medical Center. A preliminary overview using low-dose irradiation and alternating ABVD/MOPP chemotherapy. In: *Hodgkin's Disease in Children.* (ed) WA Kamps. Boston. Kluwer Academic Publishers, 1988. pp 307-315.

20. **Link MP** and Eilber FR. Osteosarcoma. In: Principles and Practice of Pediatric Oncology. (ed) P Pizzo and D Poplack. Philadelphia. J.B. Lippincott, 1989. pp 689-711.
21. Malawer MM, **Link MP** and Donaldson SS. Sarcomas of Bone. In: Cancer Principles and Practice of Oncology. Third Edition. (ed) V DeVita, S Hellman and S Rosenberg. Philadelphia. J.B. Lippincott, 1989. pp 1418-1465.
22. **Link MP**. Osteosarcoma. In: New Directions in Cancer Treatment. (ed) Ian Magrath, Springer-Verlag. 1989. pp 585-589.
23. Grier HE, Gelber RD, Clavell LA, Camitta BM, **Link MP**, Delorey MJ, Garcea MJ, and Weinstein HJ. Intensive sequential chemotherapy for children with acute myelogenous leukemia. In: Acute Leukemias II. Haematology and Blood Transfusion 33:193-197. (ed) T Buchner, G Schellong, W Hiddemann, J Ritter. Berlin, Germany. Springer Verlag, 1990.
24. Donaldson SS and **Link MP**: Childhood lymphomas: Hodgkin's disease and non-Hodgkin's lymphoma. In: Comprehensive Textbook of Oncology. Second Edition. (ed) SC Schimpff, MC Robson, and AR Moossa. Baltimore. Williams & Wilkins, 1991. pp 1514-1532.
25. **Link MP**. Osteosarcoma. In: Comprehensive Textbook of Oncology. Second Edition. (ed) SC Schimpff, MC Robson and AR Moossa. Baltimore. Williams & Wilkins, 1991. pp 1533-1545.
26. Donaldson SS and **Link MP**. Hodgkin's disease: Treatment of the young child. *Pediatr Clin North Am* 38:457-473, 1991.
27. **Link MP**, Grier HE and Donaldson SS. Bone sarcomas. In: Clinical Pediatric Oncology, 4th edition. (ed) DJ Fernbach and TJ Vietti. St. Louis. Mosby, 1991. pp 545-576.
28. **Link MP** and Donaldson SS. The lymphomas and lymphadenopathy. In: Hematology of Infancy and Childhood. Fourth Edition. (ed) D Nathan and F Oski. Philadelphia. W. B. Saunders Co., 1992. pp 1319-1353.
29. **Link MP** and Eilber FR. Osteosarcoma. In: Principles and Practice of Pediatric Oncology. Second Edition. (ed) P Pizzo and D Poplack. Philadelphia. J.B. Lippincott, 1993. pp 841-866.
30. **Link MP**. The Multi-institutional osteosarcoma study: An update. In: Osteosarcoma In Adolescents And Young Adults: New Developments And Controversies. (ed) GB. Humphrey, HS Koops, WM Molenaar, and A Postma. Boston. Kluwer Academic Publishers, 1993. pp 261-267.



31. Malawer MM, **Link MP** and Donaldson SS. Sarcomas of bone. In: Cancer Principles and Practice of Oncology. Fourth Edition (ed) V DeVita, S Hellman and S Rosenberg. Philadelphia. J.B. Lippincott, 1993. pp 1509-1566.
32. Oncology Overview: Management of primary bone tumors. **MP Link**, consulting reviewer. International Cancer Research Data bank Program, National Cancer Institute, 1993.
33. **Link MP**. Preoperative and adjuvant chemotherapy in osteosarcoma. In: Frontiers of osteosarcoma research: Interdisciplinary survey of clinical and research advances. (ed) JF Novak and JH McMaster. Seattle. Hogrefe and Huber, 1993. pp 41-49.
34. Malawer MM, **Link MP** and Donaldson SS. Sarcomas of bone. In: Cancer Principles and Practice of Oncology. Fifth Edition (ed) V DeVita, S Hellman and S Rosenberg. Philadelphia. Lippincott-Raven, 1997. pp 1789-1852.
35. **Link MP** and Eilber FR. Osteosarcoma. In: Principles and Practice of Pediatric Oncology. Third Edition. (ed) P Pizzo and D Poplack. Philadelphia. Lippincott-Raven, 1997. pp 889-920.
36. Pediatric Oncology. **MP Link**, guest editor. *Pediatr Clin North Am* 44, (4), 1997.
37. **Link MP** and Donaldson SS. The lymphomas and lymphadenopathy. In: Nathan and Oski's Hematology of Infancy and Childhood. Fifth Edition. (ed) DG Nathan and SH Orkin. Philadelphia. W. B. Saunders Co., 1998. pp 1323-1358.
38. Malawer MM, **Link MP** and Donaldson SS. Sarcomas of bone. In: Cancer Principles and Practice of Oncology. Sixth Edition (ed) V DeVita, S Hellman and S Rosenberg. Philadelphia. Lippincott Williams and Wilkins, 2001. pp 1891-1935.
39. **Link MP**, Gebhardt MC, Meyers PA. Osteosarcoma. In: Principles and Practice of Pediatric Oncology. Fourth Edition. (ed) P Pizzo and D Poplack. Philadelphia. Lippincott Williams & Wilkins, 2002. pp 1051-1089.
40. Twist CJ and **Link MP**. Assessment of lymphadenopathy in children. *Pediatr Clin North Am* 49:1009-1025, 2002.
41. **Link MP** and Donaldson SS. The lymphomas and lymphadenopathy. In: Nathan and Oski's Hematology of Infancy and Childhood. Sixth Edition. (ed) DG Nathan, SH Orkin, D Ginsburg, and AT Look. Philadelphia. W. B. Saunders Co., 2003. pp 1333-1374.

42. Sandlund JT and **Link MP**. Malignant lymphomas in childhood. In: Hematology: Basic Principles and Practice. Fourth Edition. (ed) R Hoffman, EJ Benz, SJ Shattil, B Furie, HJ Cohen, LE Silberstein, and P McGlave. Philadelphia. Elsevier Churchill Livingstone, 2005. pp 1421-1435.
43. **Link MP** and Weinstein HJ. Malignant Non-Hodgkin Lymphomas in Children. In: Principles and Practice of Pediatric Oncology. Fifth Edition. (ed) P Pizzo and D Poplack. Philadelphia. Lippincott Williams & Wilkins, 2006. pp 722-747.
44. **Link MP**, Gebhardt MC, Meyers PA. Osteosarcoma. In: Principles and Practice of Pediatric Oncology. Fifth Edition. (ed) P Pizzo and D Poplack. Philadelphia. Lippincott Williams & Wilkins, 2006. pp 1074-1115.

**APPEARS THIS WAY  
ON ORIGINAL**

**LETTERS, EDITORIALS AND MISCELLANEOUS CONTRIBUTIONS**

1. **Link M** and Vietti T. Reply: Role of Adjuvant Therapy in the Treatment of Osteosarcoma. (Letter). *Cancer Treat Rep* 67:744-745, 1983.
2. Somma C, Miller JJ, Silverman ED, **Link MP**. Abnormal Helper:Suppressor T-cell ratio in the staff of a pediatric hospital. (Letter) *N Engl J Med* 312:1573-1574, 1985.
3. Smith SD, **Link MP**, Trela M, Amylon M, Sklar J, Morgan R and Hecht F. Chromosome 9 abnormalities in childhood T-cell leukemia. (Letter) *N Engl J Med* 315:195-196, 1986.
4. Donaldson SS and **Link MP**. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. (Letter). *J Clin Oncol* 6:180, 1988.
5. **Link MP**. Treatment of osteosarcoma (Letter). *Lancet* 1:1334, 1988.
6. Donaldson SS, **Link MP**, Plowman PN, Malpas JS. Reply: Treatment of childhood Hodgkin's disease. (Letter). *J Clin Oncol* 9:528-529, 1991.
7. Simone JV, Meyer WH, and **Link, MP**. Osteosarcoma: Good news despite crude tools. *J Clin Oncol* 10:1-2, 1992.
8. **Link MP**. Cases in Hematology/Oncology. In: Nelson self-assessment in pediatrics. A continuing medical education supplement. (ed) C Prober and R Behrman. Philadelphia. WB Saunders Co., 1992.
9. **Link MP**. Commentary on the use of presurgical chemotherapy: In: Osteosarcoma In Adolescents And Young Adults: New Developments And Controversies. (ed) GB. Humphrey, HS Koops, WM Molenaar, and A Postma. Boston. Kluwer Academic Publishers, 1993. pp 383-385.
10. **Link, MP**. Editorial commentary. In: Oncology Overview: Management of primary bone tumors. International Cancer Research Data bank Program, National Cancer Institute, 1993.
11. O'Reilly R, **Link M**, Fletcher B, Gebhardt M, Krance R, Meyers P, Neff J, Schwartz C. NCCN pediatric osteosarcoma practice guidelines. The National Comprehensive Cancer Network. *Oncology* 10:1799-1806, 1812, 1996.
12. Arceci R, Ettinger A, Forman E, Haase GM, Hammond GD, Hoffman R, Kupst MJ, **Link MP**, Lustig CP, Traynor DS. National action plan for childhood cancer: Report of the National Summit Meetings on Childhood Cancer. *CA Cancer J Clin* 52:377-379, 2002.

13. Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, **Link MP**, Lustig C, Mclaughlin J, Reid LD, Turrisi AT, Unutzer J, Vernon SW. National Institutes of Health State-of-the-Science Conference statement: Symptom management in cancer: Pain, depression, and fatigue, July 15-17, 2002. *J Natl Cancer Inst* 95:1110-1117, 2003.
14. Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, **Link MP**, Lustig C, Mclaughlin J, Reid LD, Turrisi AT, Unutzer J, Vernon SW. National Institutes of Health State-of-the-Science Conference statement: Symptom management in cancer: Pain, depression, and fatigue, July 15-17, 2002. *J Natl Inst Monogr* 32:9-16, 2004.

APPEARS THIS WAY  
ON ORIGINAL

**ABSTRACTS**

1. **Link MP** and Alter BP. Fetal erythropoiesis in transient erythroblastopenia of childhood. *Pediatr Res* 13:435, 1979. (Presented).
2. Goorin A, **Link M**, Jaffe N, Riseborough T, Watts H and Abelson HT. Adjuvant chemotherapy (chemo) and limb salvage procedures for osteosarcoma--a seven year experience. *Proc Am Soc Clin Oncol* 21:472, 1980. (Presented).
3. Frantz CN, Gelber RT, Belli JA, Cassady JR, Levy R, Altman A, Quinn JJ and **Link MP**. Aggressive treatment of neuroblastoma. Proceedings of the XIIIth Annual Meeting of the International Society of Pediatric Oncology, 1981.
4. Glader BE and **Link MP**. Lymphocyte adenosine deaminase activity: A potential marker of minimal residual disease in T-cell leukemia/lymphoma. *Blood* 58:139a, 1981.
5. Finlay JL, **Link MP**, Shatsky MG and Glader BE. Influence of T-lymphocyte depletion by monoclonal antibodies on human peripheral blood erythroid colony (BFU-E) growth. *Blood* 58:96a, 1981.
6. Shatsky MG, Finlay JL, **Link MP** and Glader BE. Enhancement of human peripheral blood erythroid colony (BFU-E) growth in vitro by a glass bead column adherence technique. *Blood* 58:102a, 1981.
7. **Link M**, Berberich R, Donaldson S, Mott M, Wilbur J, Burke J and Glader B. Improved prognosis for children with advanced non-Hodgkin's lymphoma. *Proc Am Soc Clin Oncol* 1:162, 1982. (Presented).
8. Glader BE, **Link MP**, Amylon MD and Backer K. Adenosine deaminase (ADA) activity in bone marrow mononuclear cells: A marker of minimal disease in T-cell leukemia/lymphoma. *Pediatr Res* 16:205a, 1982. (Presented).
9. Goorin AM, Delorey MJ, Williamson KR, Levey R, Tapper D, **Link M** and Abelson HT: Outcome of patients (pts) who develop pulmonary (pul) metastatic (met) disease after adjuvant (adj) chemotherapy (chemo) for osteosarcoma (os). *Proc Am Soc Clin Oncol* 1:184, 1982. (Presented).
10. Paryani SB, Donaldson SS, Amylon MD and **Link MP**: Cranial nerve involvement in children with leukemia and lymphoma. *Int J Radiat Oncol Biol Phy* 8(104), 1982. (Presented).
11. Shatsky M, **Link M** and Finlay J. Enrichment of erythroid (BFU-E) and myeloid (CFU-C) colonies from human peripheral blood by a glass bead adherence technique. International Society of Hematology, 1982. (Poster session).

12. Glader BE, **Link MP**, Amylon MD, Perrine SP and Backer K. Heterogeneity of acute lymphoblastic leukemia (ALL) as revealed by adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) activity. *Blood* 60 (Suppl 1): 126a, 1982. (Poster session).
13. Amylon MD, **Link MP** and Glader BE. Immune thrombocytopenia associated with acute non-lymphocytic leukemia (ANLL). *Clin Res* 31:115A, 1983.
14. Goorin A, Delorey M, Jaffe N, **Link M**, Price K, Gelber R, Emans J, Watts H and Abelson HT: Adjuvant chemotherapy using weekly (W) vincristine (V)/high dose methotrexate (HDMTX)/Leucovorin rescue (LV) and Adriamycin (A) after ablative (AMP) or limb sparing (R) surgery (Study III) for patients with osteogenic sarcoma. *Proc Am Soc Clin Oncol* 2:236, 1983. (Presented).
15. Carroll W, Kempson R, Govan D, Freiha F, Shochat S and **Link M**. Management of testicular endodermal sinus tumors in childhood. *Proc Am Soc Clin Oncol* 2:68, 1983. (Presented).
16. Smith SD, Shatsky MR, **Link MP**, Warnke RA and Glader BE. Continuous growth of malignant T-cells in vitro: Concordance between patient's cells and cell lines by monoclonal antibody and enzyme analysis. *Blood* 62:197a, 1983.
17. Glader BE, **Link MP**, Amylon MD and Backer K: Adenosine deaminase (ADA) activity in bone marrow (BM) mononuclear cells: A sensitive biochemical marker of minimal disease in patients with T-cell leukemia/lymphoma. *Blood* 62:172a, 1983. (Poster Session).
18. Perrine SP, Parker BR, Silverman FN, Backer K, **Link MP**, Zwerdling T and Glader BE: Biochemical and radiologic diagnosis of leukemia in a hematologically normal child. *Clinical Res* 32:104A, 1984. (Presented).
19. Grier H, Camitta B, **Link M**, Coral F, Gelber R, Delorey M and Weinstein H. A seven-year experience with intensive post-remission chemotherapy for childhood acute myelogenous leukemia (AML). *Blood* 62:203a, 1983. (Poster Session).
20. **Link M**, Donaldson S, Berard C and Murphy S. Effective therapy with reduced toxicity for children with localized non-Hodgkin's lymphoma (NHL). For the Pediatric Oncology Group. *Proc Am Soc Clin Oncol* 3:251, 1984. (Presented).
21. Gelber R, Grier H, Price K, Camitta B, **Link M**, Coral F, Delorey M and Weinstein H: Prognostic factors for childhood acute myelogenous leukemia (AML). *Proc Am Soc Clin Oncol* 3:196, 1984. (Poster Session).

22. Bunin N, Hvizdala E, **Link M**, Callihan T, Hustu HO, Wharam M, Berard C, and Murphy S. Mediastinal non-lymphoblastic lymphomas (NLBL) in children: Clinicopathologic features. Proc Am Soc Clin Oncol 3:240, 1984. (Presented).
23. Carroll WL, Amylon MD, **Link MP**, Backer K and Glader BE. Childhood monosomy 7 syndrome: A familial disorder? *Pediatr Res* 18:237a, 1984. (Presented).
24. Donaldson SS, Russell KJ and **Link M**. Patterns of relapse in pediatric Hodgkin's disease. Proceedings of the XVIth Annual Meeting of the International Society of Pediatric Oncology, 1984.
25. **Link M**, Goorin A, Miser A, Green A, Pratt C, Belasco J, Pritchard J, Baker A, Kirkpatrick J, Ayala A, Shuster J, Abelson H and Simone J. The role of adjuvant chemotherapy in the treatment of osteosarcoma of the extremity: Preliminary results of the Multi-Institutional Osteosarcoma Study. NIH Consensus Development Conference on Limb-Sparing Treatment of Adult Soft-tissue and Osteogenic Sarcoma. December 3-5, 1984, Bethesda, Maryland. (Invited lecture).
26. Goorin AM, Delorey M, Price K, Gelber R, Jaffe N, **Link M**, Abelson HT, Frei E. The Dana-Farber Cancer Center Institute/Children's Hospital Adjuvant Chemotherapy Trials for Osteosarcoma. NIH Consensus Development Conference on Limb-Sparing Treatment of Adult Soft-Tissue and Osteogenic Sarcomas. December 3-5, 1984, Bethesda, MD. (Invited lecture).
27. Amylon MD, **Link MP**, Perrine SP, Shochat SJ, Donaldson SS and Glader BE. Neuroblastoma in infants: When is therapy necessary? *Pediatric Res* 19:257A, 1985.
28. Grossi CE, Crist WM, Cleary ML, Prasthofer EF, Heggie GD, Omura G, Carroll AJ, **Link MP** and Sklar J. Acute leukemias associated with the 4;11 chromosome translocation have rearranged immunoglobulin (Ig) heavy chain (HC) genes. Proc Am Soc Clin Oncol 4:169, 1985. (Presented).
29. Donaldson SS and **Link MP**. Long-term results in pediatric Hodgkin's disease - treatment with MOPP and low dose radiotherapy. Proc Am Soc Clin Oncol 4:200, 1985. (Presented).
30. **Link M**, Goorin A, Miser A, Green A, Pratt C, Belasco J, Pritchard J, Baker A, Kirkpatrick J, Ayala A, Shuster J, Abelson H, Simone J and Vietti T. The role of adjuvant chemotherapy in the treatment of osteosarcoma (OS) of the extremity: Preliminary results of the Multi-Institutional Osteosarcoma Study. Proc Am Soc Clin Oncol 4:237, 1985. (Presented, Plenary Session).
31. Kaplan LD, Ries CA, **Link MP** and Linker CA. Differentiation of acute undifferentiated leukemia in response to chemotherapy. Proc Am Soc Clin Oncol 4:169, 1985.

32. **Link M**, Goorin A, Miser A, Green A, Pratt C, Belasco J, Pritchard J, Baker A, Kirkpatrick J, Ayala A, Shuster J, Abelson H, Simone J and Vietti T. Adjuvant chemotherapy improves relapse-free survival (RFS) in osteosarcoma (OS) of the extremity. Results of the Multi-Institutional Osteosarcoma Study (MIOS). Proceedings of the XVIIth Annual Meeting of the International Society of Pediatric Oncology (pp 216-217), 1985. (Presented).
33. Finlay J, Trigg M, Mitchell T, Friedrich S and **Link M**. Protocol for poor-risk non-lymphoblastic lymphoma - results of a pilot study. Proceedings of the XVIIth Annual Meeting of the International Society of Pediatric Oncology (pp 337-339), 1985.
34. **Link MP**. Adjuvant chemotherapy with high-dose methotrexate in the treatment of osteosarcoma. Symposium for Development of Folates and Folic Acid Antagonists in Cancer Chemotherapy, January 23-26, 1986, Tarpon Springs, Florida.
35. Finlay J, Trigg M, Friedrich S and **Link M**. Poor risk non-lymphoblastic lymphoma in children: A pilot study of intensive therapy. Proc Am Soc Clin Oncol 5:199, 1986. (Presented).
36. Carroll WL, **Link MP**, Smith SD, Bologna-Vaughan S, Carswell C and Levy R. Anti-idiotypic antibodies in childhood B cell leukemia (BL). Pediatr Res 20:277a, 1986. (Presented).
37. Donaldson SS, **Link MP**, Shuster JJ, Berard C, Murphy SB. What is the role of involved field radiation among children with localized non-Hodgkin's lymphoma? Int J Radiat Oncol Biol Phys 12(Suppl 1):159, 1986. (Presented).
38. Diaz P, Amylon M, **Link M**, Smith S, and Arvin A. Safety of live varicella vaccine given to siblings of immunocompromised children to prevent household exposure to varicella. 26th ICAAC, New Orleans, LA.
39. **Link MP**, Donaldson SS, Berard CW, Shuster JJ and Murphy SB. High cure rate with reduced therapy in localized non-Hodgkin's lymphoma (NHL) of childhood. Proc Am Soc Clin Oncol 6:190, 1987. (Presented, Plenary Session).
40. Grier H, Delorey M, Camitta B, **Link M**, Blattner S, Perrine S, and Weinstein H. Acute myelogenous leukemia (AML) in infants. Proc Am Soc Clin Oncol 6:154, 1987. (Presented).
41. Donaldson SS and **Link MP**. Continual progress in the management of children with Hodgkin's disease using combined modality therapy. Third Int Conf on Malignant Lymphoma, Lugano, 1987. p 40. (Presented).



42. **Link MP**, Donaldson SS, Berard CW, Shuster JJ and Murphy SB. High cure rate with reduction in toxicity for children with localized non-Hodgkin's lymphoma: Results of a randomized study of the Pediatric Oncology Group. Third Int Conf on Malignant Lymphomas, Lugano, 1987. p. 43. (Presented).
43. Mefferd JM Donaldson SS, **Link MP**. Pulmonary, cardiac and thyroid function following combined modality therapy in pediatric Hodgkin's disease. *Int J Radiat Oncology Biol Phys* 13(Suppl 1):99, 1987.
44. Carroll AJ, **Link MP**, Ragab AH, Pullen DJ and Crist WM. A nonrandom translocation, t(1;14), in children with T-cell acute lymphoblastic leukemia. *Am J Hum Genet* 41:A24, 1987.
45. Finlay JL, Trigg ME, **Link MP**, Friedrich S, Cariro M, Cich J, Dinndorf P, Dvorak P, Ettinger L, Heyn R, Hutchinson R, McMahon D, McGuire W, Mitchell T, Nesbit M, Provisor A, Roloff J, Shahidi NT, Singher L, Sondel PM and Woods W. Poor-risk non-lymphoblastic lymphoma of childhood: Results of an intensive pilot study. *Blood* 70:245a, 1987.
46. Carroll AJ, **Link MP**, Pullen DJ, Shuster JJ and Crist WM. Cytogenetic features in children with T-cell acute lymphoblastic leukemia. *Blood* 70:276a, 1987. (Presented).
47. **Link MP**, Borowitz MJ, Behm FG, Jackson A, Brock B, Shuster JJ and Pullen J. Rapid immunodiagnosis of childhood acute lymphoblastic leukemia using a screening kit. *Proc Am Soc Clin Oncol* 7:180, 1988.
48. Goorin AM, Shuster JJ, Miser A, Meyer WH, **Link MP**. Osteosarcoma: Pattern of relapse (REL) for patients (PTS) receiving immediate (IMMED) adjuvant chemotherapy compared to PTS receiving delayed chemotherapy (DELAY) following REL. Results of the Multi-Institutional Osteosarcoma Study. *Proc Am Soc Clin Oncol* 7:258, 1988. (Presented).
49. Wright A, Clayberger C, **Link MP**, Smith SD and Krensky AM. Gamma:delta bearing cytotoxic T lymphocytes specifically lyse autologous tumor in an MHC-unrestricted fashion. *FASEB J* 2:A1827, 1988.
50. Smith LM, Donaldson SS, Egbert PR, **Link MP**, and Bagshaw MA. Aggressive management of second primary tumors in survivors of hereditary retinoblastoma. *Int J Radiat Oncology Biol Phys* 15(Suppl 1):207, 1988.
51. Russo CL, Carroll A, Amylon M, Lange W, Sklar J and **Link MP**. The Philadelphia chromosome and monosomy 7 in childhood acute leukemia. *Am J Human Genetics* 43(Suppl 3):A32, 1988. (Presented).

52. Tycko B, Palmer JD, Smith SD, Amylon M, **Link M** and Sklar J. Polymerase chain reaction (PCR) amplification of rearranged gamma T-cell receptor genes using junction-specific oligonucleotides: Application to detection of minimal residual disease in acute lymphocytic leukemia. IAP.
53. Carroll W, Yu M, **Link M**, Korsmeyer S. Immunoglobulin gene (IG) somatic mutation in Burkitt lymphoma. *Blood* 72:158a, 1988. (Presented).
54. Russo C, Carroll A, Borowitz M, Kohler S, Shannon K, Forman E, Cook B, Amylon M, Pullen J, **Link M**. The Philadelphia chromosome with monosomy 7 in childhood acute lymphoblastic leukemia. *Proc Am Soc Clin Oncol* 8:825, 1989. (Presented).
55. Wu NW, **Link M**, Stoolman L, Mandell S, Hanson C and Butcher EC. Lymphocyte-high endothelial cell venule (HEV) interaction: A model for leukemia metastasis. *Proc Am Soc Clin Oncol* 8:826, 1989. (Poster Session).
56. **Link M**, Goorin A, Horowitz M, Meyer J, Belasco J, Baker A, Ayala A and Shuster J. The Multi-Institutional Osteosarcoma Study (MIOS): Update and analysis of prognostic factors. *Med Pediatr Oncol* 17:301-302, 1989. XXIst Annual Meeting of SIOP. Prague, Czechoslovakia, Sept. 20-22, 1989. (Presented).
57. Donaldson S, Shuster J, Andreozzi C, Gilula L, **Link M**, Manning J, Neff J, Thompson E, and Vietti T. The Pediatric Oncology Group (POG) experience in Ewing's sarcoma of bone. *Med Pediatr Oncol* 17:283, 1989. XXIst Annual Meeting of SIOP. Prague, Czechoslovakia, Sept. 20-22, 1989. (Presented).
58. Shochat S, Donaldson SS, Hartman GE and **Link MP**. Staging laparotomy in childhood Hodgkin's disease: The Stanford experience. *Med Pediatr Oncol* 17:321-322, 1989. XXIst Annual Meeting of SIOP. Prague, Czechoslovakia, Sept. 20-22, 1989. (Presented).
59. Carroll AJ, **Link MP**, Amylon MD, Pullen DJ, Crist WM. A new translocation, t(1;14)(p34;q11), in T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group Study. ASH Spring Symposium 6/23-24/89, Coronado, CA.
60. Carroll AJ, **Link MP**, Amylon MD, Pullen DJ, Crist WM. A new translocation, t(1;14)(p34;q11), in T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group Study. American Society of Human Genetics.
61. Pui C-H, Carroll AJ, Head D, Raimondi SC, Land VJ, Crist WM, **Link MP**, Behm FG, Nash M, Pullen DJ and Look AT. Near-triploidy, and near tetraploidy in acute lymphoblastic leukemia (ALL) of childhood. *Proc Am Soc Clin Oncol* 9:216, 1990.

62. Goorin AM, Ayala A, Cantor A, Baker A, Harris M, and **Link M**. Very high degree of primary tumor destruction with presurgical chemotherapy (chemo) for patients with osteosarcoma (OGS) treated on the Pediatric Oncology Group (POG) 8651 (OS2). *Proc Am Soc Clin Oncol* 10:319, 1991.
63. Harris MB, Cantor A, Goorin A, Ayala A, and **Link MP**. Response to ifosfamide in patients with metastatic osteosarcoma: A comparison of results in newly diagnosed patients versus those with recurrent disease after adjuvant chemotherapy. *Proc Am Soc Clin Oncol* 10:315, 1991.
64. Ribeiro R, Pui C-H, Hvizdala E, Murphy S, Falletta J, **Link M**, Sullivan M, Pick T, Fairclough D, Sandlund J, Crist W, and Berard C. Childhood non-Hodgkin lymphoma (NHL) of rare histology. *Proc Am Soc Clin Oncol* 10:289, 1991.
65. Crist W, Shuster J, Steuber P, Pullen J, Wagner H, Laver J, Borowitz M, Look A, **Link M**, Frankel L, Amylon M, Land V. Results of recent trials of the Pediatric Oncology Group (POG) for children with acute lymphoblastic leukemia (ALL). 5th International Symposium on Therapy of Acute Leukemias, submitted. (11/1-6/91).
66. Pui C-H, Carroll AJ, Raimondi SC, Schell MJ, Head DR, Shuster JJ, Crist WM, Borowitz MJ, **Link MP**, Behm FG, Steuber CP and Land VJ. Childhood acute lymphoblastic leukemia (ALL) with isochromosomes. *Blood* 78:328a, 1991. (Poster session).
67. Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D, Behm FG, Crist WM, **Link MP**, Borowitz M, Pullen DJ. Morphologic, immunophenotypic, and cytogenetic studies at time of first marrow relapse in children with acute lymphoblastic leukemia (ALL): Comparison with results at diagnosis and effect on outcome. *Blood* 78:171a, 1991. (Presented).
68. Bash RO, Crist WM, **Link MP**, Schuster JJ, Amylon M, Buchanan GR, Baer R. Clinical features and outcome in childhood T-cell Acute Lymphoblastic Leukemia (T-ALL) with the *tal*<sup>d</sup> rearrangement. *Blood* 78:325a, 1991. (Poster session).
69. Perlman EJ, Askin FB, **Link MP**, and Grier H. Ewing's Sarcoma: Routine diagnostic utilization of MIC2 analysis. Annual meeting of United States and Canadian Academy of Pathology. *Lab Invest* 66:111A, 1992.
70. Maurer HM, Cantor A, Salzberg A, Pratt C, Thomas P, Parham D, Webber B, Marcus R, Pick T, Green D, **Link M**, Vietti T. Adjuvant chemotherapy vs observation for localized non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) in children. *Proc Am Soc Clin Oncol* 11:363, 1992 (Poster session).

71. Goorin A, Rinsky L, Lipsitz S, Gebhardt M, **Link M**. New plateau in cure rate for patients with non-metastatic osteosarcoma (OSA): Experience of the Dana Farber Cancer Institute (DFCI) and Stanford. *Proc Am Soc Clin Oncol* 11:365, 1992 (Presented).
72. Maurer HM, Cantor A, Salzberg A, Pratt C, Thomas P, Parham D, Webber B, Marcus R, Pick T, Green D, **Link M**, Vietti T. Adjuvant chemotherapy vs observation for localized non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) in children. *Med Pediatr Oncol* 20:388, 1992. XXIVth Annual Meeting of SIOP. Hanover, Germany, Oct. 12-16, 1992 (Presented).
73. Cleary SF, Donaldson SS, **Link MP**. Management of Hodgkin's disease in the very young. *Int J Rad Onc Biol Phys* 24(Suppl 1):223-224, 1992.
74. Amylon MD, Carroll AJ, **Link MP**, Katz JA, Shuster JJ. Second malignancies in children treated with teniposide (VM-26) for T-cell lymphoid malignancy: A role for asparaginase? [A Pediatric Oncology Group (POG) study]. *Blood* 80: 206a, 1992 (Poster session).
75. Naumovski L, Stevens S, Barsh G, **Link MP**, Cleary ML. Characterization of mice transgenic for the oncogenic helix-loop-helix protein *lyl-1*. *Blood* 80:301a, 1992 (Poster session).
76. Lumadue JA, **Link M**, Perlman EJ. The use of MIC2 analysis in differentiating small cell carcinoma (SCC) from peripheral neuroectodermal tumors (PNET). Annual meeting of United States and Canadian Academy of Pathology. *Lab Invest* 67:8A, 1993.
77. Riopel MA, Dickman PS, **Link M**, Perlman EJ. MIC2 analysis in pediatric lymphomas. Annual meeting of United States and Canadian Academy of Pathology. *Lab Invest* 67:128A, 1993.
78. Murphy SB, Amylon M, **Link MP**, Bowman WP, Brecher M, Pick T, Berard CW, Hutchinson R, Shuster JJ. Recent advances in therapy of high-grade T- and B-cell non-Hodgkin's Lymphomas (NHL) of childhood. Keystone Symposium on T- and B-cell Tumors. April 17-23, 1993. *J Cell Biochem (suppl)* 17E:257, 1993.
79. **Link MP**, Shuster JJ, Berard CW, Murphy SB. Nine weeks of chemotherapy without radiotherapy is sufficient treatment for most children with localized non-Hodgkin's lymphoma (NHL). *Proc Am Soc Clin Oncol* 12:384, 1993 (Presented).
80. Hunger SP, **Link MP**, Donaldson SS. Long-term results of ABVD/MOPP and low dose involved field radiotherapy (LD IFXRT) in pediatric Hodgkin's Disease (HD): The Stanford experience. *Proc Am Soc Clin Oncol* 12:384, 1993 (Presented).

81. Katz J, Shuster J, Schneider N, Amylon M, **Link M**, Carroll A. The significance of ploidy in childhood T-cell acute lymphoblastic leukemia (T-ALL): A Pediatric Oncology Group (POG) study. *Proc Am Soc Clin Oncol* 12:316, 1993 (Presented).
82. Hutchison RE, Berard CW, Shuster JJ, **Link MP**, Pick TE, and Murphy SB. Immunophenotype influences survival in pediatric large cell lymphoma. A Pediatric Oncology Group study. Fifth Int Conf on Malignant Lymphomas, Lugano, 1993 (Presented).
83. **Link MP**, Shuster JJ, Donaldson SS, Berard CW, and Murphy SB. Treatment of children with localized non-Hodgkin's lymphoma (NHL) with nine weeks of chemotherapy without radiotherapy. *Med Pediatr Oncol* 21:532, 1993. XXVth Annual Meeting of SIOP. San Francisco, October 5-9, 1993 (Presented).
84. Donaldson SS, Hunger SP, and **Link MP**. A new level of success in treatment of children with Hodgkin's disease: The Stanford experience with low dose, involved field radiation and MOPP/ABVD chemotherapy. *Med Pediatr Oncol* 21:543, 1993. XXVth Annual Meeting of SIOP. San Francisco, October 5-9, 1993 (Presented).
85. Rubnitz JF, **Link MP**, Shuster JJ, Carroll AJ, Hakami N, Frankel L, Pullen DJ, and Cleary ML. Frequency and significance of HRX rearrangements in infant leukemia. *Blood* 82: 190a, 1993 (Presented).
86. Yu AL, Heung RC, Uttenreuther M, Kim J, **Link MP**, Ochs J, Buchanan GR, Amylon M, Vietti T. Phase I trial of XomaZyme-H65 (H65-RTA) in children with T cell acute lymphoblastic leukemia/lymphoma: A Pediatric Oncology Group (POG) study (POG 9074). *Proc Am Assoc Cancer Res* 35:211, 1994.
87. **Link MP**, Hudson M, Donaldson SS, Greenwald C, Kun L, Tarbell N, and Weinstein HJ. Treatment of children with unfavorable and advanced stage Hodgkin's disease with vinblastine, etoposide, prednisone and adriamycin (VEPA) and low-dose, involved field irradiation. *Proc Am Soc Clin Oncol* 13:392, 1994 (Presented).
88. Grier H, Krailo M, **Link M**, Tarbell N, Fryer C, Pritchard D, Gebhardt M, Dickman P, Perlman E, Meyer P, Moore S, Raussen P, Vietti T, Miser J for POG and CCG. Improved outcome in non-metastatic Ewing's sarcoma (EWS) and PNET of bone with the addition of ifosfamide(I) and etoposide (E) to vincristine (V), adriamycin(Ad), cyclophosphamide(C), and actinomycin(A): A Childrens Cancer Group (CCG) and Pediatric Oncology Group (POG) report. *Proc Am Soc Clin Oncol* 13:421, 1994 (Presented, Plenary Session).
89. Goorin AM, Cantor A, and **Link MP**. A phase I trial of etoposide (VP) and escalating doses of ifosfamide (IFOS) plus GCSF in recurrent pediatric sarcomas. *Proc Am Soc Clin Oncol* 13:425, 1994.

90. Mahmoud H, Schwartz C, Shuster J, Pui CH, Behm F, Amylon M, Raimondi S, Borowitz M, **Link M**, Pullen J, Camitta B, Hakami N, Crist W, Carroll A. The (11;19) translocation is associated with poor outcome in infants with acute lymphoblastic leukemia. A collaborative study of the POG and SJCRH. *Med Pediatr Oncol* 23:199, 1994. XXVIth Annual Meeting of SIOP. Paris, September, 1994 (Poster session).
91. Donaldson SS, Hudson M, **Link MP**, Greenwald C, Kun L, Tarbell NJ, and Weinstein HJ. Treatment of children with early stage and favorable Hodgkin's Disease--A model of success. *Proc Am Soc Clin Oncol* 14:408, 1995 (Presented).
92. Goorin A, Baker A, Gieser P, Ayala A, Gebhardt M, Harris M, Weiner M, Cantor A, Grier H, Vietti T, and **Link M**. No evidence for improved event-free survival [EFS] with presurgical chemotherapy [PRE] for non-metastatic extremity osteogenic sarcoma [OGS]: Preliminary results of randomized Pediatric Oncology Group [POG] trial 8651. *Proc Am Soc Clin Oncol* 14:444, 1995 (Presented).
93. Harris M, Geiser P, **Link M**, Goorin A, Ayala A, Shochat S, Ferguson W, and Holbrook T. Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group study. *Proc Am Soc Clin Oncol* 14:445, 1995 (Presented).
94. Goorin AM, Geiser P, and **Link MP** for the Pediatric Oncology Group. Response rate in recurrent osteosarcoma with etoposide {VP} and escalating doses of ifosfamide {IFOS} plus GCSF. *Med Pediatr Oncol* 25:310, 1995. XXVIIth Annual Meeting of SIOP. Montevideo, October 10-14, 1995 (Poster session).
95. Haines DS, Kurz BW, **Link MP**, Ng E, Shuster JJ, Lauer SJ, Brodsky, I and Marks DI. p53 inactivation in poor outcome acute lymphoblastic leukemia (ALL) at diagnosis. *Blood* 86:730a, 1995.
96. Lawrence HJ, Sauvageau G, Kraft D, Waller N, Lopez AR, **Link MP**, Humphries RK, Largman C. Stage-specific expression of the *HOXC4* homeobox gene during T and B cell ontogeny. *Blood* 86:302a, 1995 (Poster session).
97. Behm FG, Carroll A, Shuster J, Camitta B, **Link M**, Lauer S, Land V, Steuber P, Crist W, Pullen J. *MLL* rearrangement predicts a high risk of failure in children  $\geq 1$  year of age with precursor-B ALL. A Pediatric Oncology Group study. *Proc Am Assoc Cancer Research* 37:186, 1996.
98. Ferguson W, Harris M, **Link M**, Gebhardt M, Shochat S, Siegal GP, Goorin A, Grier H. Carboplatin in the treatment of newly-diagnosed metastatic or unresectable osteosarcoma: A Pediatric Oncology Group study. *Proc Am Soc Clin Oncol* 15:521, 1996 (Presented).

99. Miser JS, Krailo M, Meyers P, Rausen A, **Link M**, Tarbell N, Fryer C, Pritchard D, Gebhardt M, Dickman P, Pearlman E, Moore S, Vietti T, Grier H. Metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone: Failure of new regimens to improve outcome. Proc Am Soc Clin Oncol 15:467, 1996 (Presented).
100. Haines DS, Marks DI, Kurz BI, **Link MP**, Ng E, Shuster JJ, Lauer SJ, Carroll D, Brodsky, I. MDM-2 overexpression and p53 gene mutation at diagnosis are associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 14:1749, 1996 (Poster session).
101. Hutchison RE, Banki K, Shuster JJ, Barrett D, Dieck C, Berard CW, Murphy SB, **Link MP**, Pick TE, Laver J, Schwenn M, Mathew P, Morris SW. Use of an anti-ALK antibody in the characterization of anaplastic large cell lymphoma of childhood. Sixth international conference on malignant lymphoma. Lugano, 1996 (Presented).
102. **Link MP**, Goorin AM, Wexler LH, Meyer WH, Belasco J, Baker A, Ayala A, Shuster JJ. Adjuvant chemotherapy of osteosarcoma: End results of the multi-institutional osteosarcoma study (MIOS). Med Pediatr Oncol 27:250, 1996. XXVIIIth Annual Meeting of SIOP. Vienna, October 1-5, 1996 (Presented).
103. Goorin A, Gieser P, Schwartzentruber D, Wexler L, Ayala A, Gebhardt M, Harris M, Grier H, Vietti T, and **Link M**. No evidence for improved event-free survival with presurgical chemotherapy [PRE] for non-metastatic extremity osteosarcoma. Preliminary results of randomized Pediatric Oncology Group trial 8651: An update. Med Pediatr Oncol 27:263, 1996. XXVIIIth Annual Meeting of SIOP. Vienna, October 1-5, 1996 (Presented).
104. Ruymann F, Crist W, Gehan E, Weiner E, **Link M**, Qualman S, Wharam M, Anderson J, Maurer H, for the IRSG of CCG and POG. Evaluation of three doublet chemotherapy regimens in metastatic rhabdomyosarcoma in IRSG-IV. Med Pediatr Oncol 27:337, 1996. XXVIIIth Annual Meeting of SIOP. Vienna, October 1-5, 1996 (Poster session).
105. Grier H, Krailo M, Tarbell N, **Link M**, Fryer C, Pritchard D, Gebhardt M, Dickman P, Pearlman E, Meyers P, Moore S, Donaldson S, Rausen A, Vietti T, Miser J for POG and CCG. Adding ifosfamide (I) and etoposide (E) to vincristine (V), cyclophosphamide (C) Adriamycin (Ad) and actinomycin (A) improves outcome in non-metastatic Ewing's (EWS) and PNET: Update of CCG/POG study. Med Pediatr Oncol 27:259, 1996. XXVIIIth Annual Meeting of SIOP. Vienna, October 1-5, 1996 (Presented).
106. Goorin A, Gieser P, Schwartzentruber D, Wexler L, Ayala A, Gebhardt M, Harris M, Grier H, Vietti T, and **Link M**. No evidence for improved event-free survival with presurgical chemotherapy [PRE] for non-metastatic extremity osteosarcoma. Preliminary results of randomized Pediatric Oncology Group trial 8651, an update. 2nd Osteosarcoma Research Conference. Istituto Ortopedici Rizzoli. Bologna, Italy.

107. Rubnitz JE, Shuster JJ, Land VJ, **Link MP**, Pullen DJ, Camitta BM, Pui C-H, Downing JR and Behm FG. Case-control study of children with acute lymphoblastic leukemia confirms the favorable prognostic impact of *TEL* gene rearrangements: A Pediatric Oncology Group study. *Blood* 88:450a, 1996 (Presented).
108. Maloney KW, Rubnitz JE, Cleary ML, Frankel L, Hakami N, **Link MP**, Pullen DJ and Hunger SP. Lack of *ETV6 (TEL)* rearrangements in infant acute lymphoblastic leukemia (ALL). *Blood* 88:72a, 1996 (Poster session).
109. Geaghan S, Amylon M, and **Link M**. Pediatric acute lymphoblastic leukemia with eosinophilia and t(5;14). *Blood* 88:155b, 1996.
110. Yu AL, Batova A, Diccianni MB, Pullen J, **Link MP**, and Yu J. Preferential inactivation of P15<sup>INK4B</sup> but not P16<sup>INK4A</sup> by hypermethylation in T cell acute lymphoblastic leukemia. *Blood* 88:355a, 1996 (Poster session).
111. Batova A, Diccianni MB, Yu JC, Nobori T, **Link MP**, Pullen J, and Yu AL. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia (T-ALL). *Proc Amer Assoc Cancer Research* 38:276, 1997.
112. Suryanarayan K, Shuster JJ, Donaldson SS, Berard CW, Murphy SB, and **Link MP**. Successful treatment of localized primary lymphoma of bone in children without radiotherapy. *Proc Am Soc Clin Oncol* 16:516a, 1997 (Presented).
113. Maloney KW, Rubnitz JE, Cleary ML, Frankel L, Hakami N, **Link MP**, Pullen DJ, and Hunger SP. Lack of homozygous p16<sup>INK4A</sup> (p16) or p15<sup>INK4B</sup> (p15) gene deletions in infant acute lymphoblastic leukemia (ALL). *Proc Am Soc Clin Oncol* 16:515a, 1997 (Presented).
114. Anderson JR, Ruby E, **Link M**, Crist W, and Maurer H. Identification of a favorable subset of patients (PTS) with metastatic (MET) rhabdomyosarcoma (RMS): A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). *Proc Am Soc Clin Oncol* 16:510a, 1997 (Presented).
115. Miser J, Krailo M, Smith M, Rubenstein L, Meyers P, Rausen A, **Link M**, Tarbell N, Fryer C, Pritchard D, Gebhart M, Dickman P, Pearlman E, Moore S, Vietti T, and Grier H. Secondary leukemia (SL) or myelodysplastic syndrome (MDS) following therapy for Ewing's sarcoma (ES). *Proc Am Soc Clin Oncol* 16:518a, 1997 (Presented).
116. Ruymann F, Crist W, Wiener E, **Link M**, Qualman S, Wharam M, Anderson J, and Maurer H. Comparison of two doublet chemotherapy regimens and conventional radiotherapy in metastatic rhabdomyosarcoma: Improved overall survival using ifosfamide/etoposide compared to vincristine/melphalan in IRSG-IV. *Proc Am Soc Clin Oncol* 16:521a, 1997 (Poster session).



117. Vietti T, Crist W, Ruby E, Raney B, Ruymann F, **Link M**, Grier H, Maurer H for the Intergroup RMS Study Group (IRSG). Topotecan window in patients with rhabdomyosarcoma (RMS): An IRSG study. Proc Am Soc Clin Oncol 16:510a, 1997 (Presented).
118. Anderson JR, **Link M**, Arndt C, and Maurer H for the IRS Group (IRSG). Prognostic factors defining risk categories for the treatment of rhabdomyosarcoma (RMS) patients on intergroup RMS study (IRS) V. Third International Congress on Soft Tissue Sarcoma in Children and Adolescents. Stuttgart, April 30 - May 3, 1997.
119. Anderson JR, Ruby E, **Link M**, Miser J, Crist W, and Maurer H for the IRSG. Identification of a favorable subset of patients (pts) with metastatic (met) rhabdomyosarcoma (RMS): A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Third International Congress on Soft Tissue Sarcoma in Children and Adolescents. Stuttgart, April 30 - May 3, 1997.
120. **Link MP**, Suryanarayan K, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. Successful treatment of localized primary lymphoma of bone in children without radiotherapy. Med Pediatr Oncol 29: 376, 1997. XXIXth Annual Meeting of SIOP. Istanbul, September 23-27, 1997 (Presented)
121. Laver J, Mahmoud HH, Amylon MD, Desai S, **Link MP**, Schwenn MR, and Shuster JJ. Randomized trial of r-metHuG-CSF in an intensive program for T-cell Leukemia and advanced stage lymphoblastic lymphoma. A Pediatric Oncology Group Study (POG #9398). Med Pediatr Oncol 29:333, 1997. XXIXth Annual Meeting of SIOP. Istanbul, September 23-27, 1997 (Presented)
122. Uner AH, **Link MP**, Laver J, Schwenn M, Morris SW, Pulford K, Mason DY, Barrett D, Hutchison RE. Detection of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) in pediatric large cell lymphoma using monoclonal antibody ALK 1. Med Pediatr Oncol 29:345, 1997. XXIXth Annual Meeting of SIOP. Istanbul, September 23-27, 1997 (Presented)
123. Donaldson S, Torrey M, **Link M**, Glicksman A, Laurie F, Manning J, Neff J, Thompson E, Shuster J. A multi-disciplinary study investigating radiotherapy in Ewing's sarcoma--A final report of POG 8346. Int J Radiat Oncol Biol Phys 39(suppl):141, 1997. 39th annual meeting of the American Society for Therapeutic Radiology and Oncology, 1997 (Presented).
124. Hunger SP, Fall MZ, Camitta BM, Carroll AJ, **Link MP**, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Steuber CP, and Cleary ML. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias (ALLs) with a t(1;19)(q23;p13): A Pediatric Oncology Group (POG) study. Blood 90:423a, 1997 (Presented).

125. **Link MP**, Shuster JJ, Hutchison RE, Schwenn MR, Donaldson SS, Murphy SB. Minimizing therapy for children with localized non-Hodgkin's lymphomas of the gastrointestinal tract. Proc Am Soc Clin Oncol 17:528a, 1998 (Presented).
126. Goorin AM, Gieser P, Ferguson W, Harris M, **Link M**, Gebhardt M, Siegal GP, Shamberger RC, Bernstein M, Schwartz C, Berrey H, Grier, HE. Successful phase II trial of etoposide and high dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group trial. Proc Am Soc Clin Oncol 17:535a, 1998 (Poster session).
127. Anderson JR, **Link M**, Qualman S, Maurer HM, Crist WM for the IRS Group. Improved outcome for patients (pts) with embryonal (emb) histology (hist) but not alveolar hist rhabdomyosarcoma (rms): Results from Intergroup Rhabdomyosarcoma Study IV (IRS-IV). Proc Am Soc Clin Oncol 17:526a, 1998.
128. Goorin AM, Gieser P, Ferguson W, Harris M, **Link M**, Gebhardt M, Siegal GP, Shamberger RC, Bernstein M, Schwartz C, Berrey H, Grier, HE. Successful phase II trial of etoposide and high dose ifosfamide in newly diagnosed metastatic osteosarcoma: An update. A Pediatric Oncology Group trial (POG). Med Pediatr Oncol 31:231, 1998. XXXth Annual Meeting of SIOP. Yokohama, October 4-8, 1998.
129. Rubnitz JE, Camitta BM, Raimondi SC, Carroll AJ, Borowitz MJ, Shuster JJ, **Link MP**, Pullen DJ, Downing JR, Behm FG, Mahmoud H, Pui C-H. Childhood acute lymphoblastic leukemia with the *MLL-ENL* fusion and t(11;19)(q23;p13): Favorable prognosis in T-Cell Cases. Blood 92:312a, 1998 (Presented).
130. Goorin AM, Gieser P, Ferguson W, Harris M, **Link M**, Gebhardt M, Siegal GP, Shamberger RC, Bernstein M, Schwartz C, Berrey H, Grier, HE. Successful phase II trial of etoposide and high dose ifosfamide in newly diagnosed metastatic osteosarcoma: Preliminary report. A Pediatric Oncology Group Trial (POG). Connective Tissue Oncology Society, presented.
131. Sandler E, Lyden E, Ruymann F, Maurer H, Wharam M, Parham D, **Link M**, Crist W. Efficacy of ifosfamide (IFOS) and doxorubicin (DOX) given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma (RMS): A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Proc Am Soc Clin Oncol 18:562a, 1999.
132. Harney E, Cochrane D, Marina N, Bernstein M, **Link MP**. Phase I trial of pegylated liposomal doxorubicin (DOXIL) in children with solid tumors. Proc Am Soc Clin Oncol 18:556a, 1999.
133. Laver JH, Barredo JC, Amylon M, Kurtzberg J, Camitta BM, Pullen J, **Link M**, Ravindranath Y, Murphy SB, Shuster, J. Effects of cranial radiation in children with high risk T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group report. Proc Am Soc Clin Oncol 18:565a, 1999.

134. Hutchison RE, Finch C, Kepner J, Fuller C, Bowman P, Link M, Schwenn M, Laver J, Desai S, Barrett D, Murphy SB. Burkitt-like lymphoma is immunophenotypically different from Burkitt lymphoma in young persons. Seventh international conference on malignant lymphoma. Lugano, June 2-5, 1999 (Presented).
135. Crist W, Anderson J, Lobe T, Wharam M, Qualman S, Raney RB, Ruymann F, Womer RB, Meyer W, **Link M**. Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma (RMS): A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). *J Pediatr Hematol Oncol* 21:323-4, 1999.
136. Schwartzenruber DJ, Goorin AM, Gebhardt MC, Gieser P, Ayala A, Harris M, Grier H, **Link M**. Pre-surgical chemotherapy vs immediate surgery and adjuvant chemotherapy for non-metastatic osteosarcoma. Surgical results of POG 8651. Annual meeting of the Connective Tissue Oncology Society (CTOS).
137. Goorin AM, Devidas M, Gieser P, Ferguson W, Harris M, **Link M**, Gebhardt M, Siegal GP, Shamberger RC, Bernstein M, Schwartz C, Berrey H, Grier HE. Successful phase II trial of etoposide and high dose ifosfamide in newly diagnosed metastatic osteosarcoma: An update. A Pediatric Oncology Group trial (POG). Annual meeting of the Connective Tissue Oncology Society (CTOS).
138. Weinstein HJ, Hudson M, **Link MP**, Billett AL, Kun L, Narbell NJ, Donaldson SS. VAMP chemotherapy and involved field irradiation (IF) for early stage Hodgkin's disease. *Pediatr Res*, submitted (Presented).
139. Maurer HM, Anderson J, Meza J, **Link M**, Crist W. Alveolar rhabdomyosarcoma: Analysis of the total IRS experience.
140. Smith LM, Anderson JR, Qualman SJ, Crist WM, Paidas CN, Pappo AS, **Link MP**, Grier HE, Wiener ES, Breneman JC, Raney RB, Donaldson SS. Which patients with rhabdomyosarcoma (Rms) and microscopic residual tumor (group II) fail therapy? A report from the Intergroup Rhabdomyosarcoma Study Group (IrsG). *Proc Am Soc Clin Oncol* 19:577a, 2000.
141. Arndt C, Donaldson S, Andrassy R, Anderson J, Laurie F, **Link M**, Raney RB, Maurer H, Crist W for the Intergroup Rhabdomyosarcoma Study Group (IRSG). What constitutes optimal therapy for rhabdomyosarcoma (RMS) of the female genitourinary tract? *Med Pediatr Oncol* 35:178, 2000. XXXIInd Annual Meeting of SIOP. Amsterdam, October 4-7, 2000.
142. Shuster J, **Link M**, Camitta B, Pullen J, Behm F. Group sequential design of case-control studies for pediatric acute lymphoblastic leukemia cell banks. International Society for Clinical Biostatistics. Trent, Italy, September 4-8, 2000.

143. Winter SS, Sweatman JJ, Shuster JJ, Amylon MD, **Link MP**, Larson RS. Bone marrow stroma-supported recovery of T-lineage acute lymphoblastic leukemia (T-ALL) cells is prognostic of treatment outcome: A Pediatric Oncology Group study. *Blood* 96:111a, 2000 (Poster session).
144. Vajpayee N, Kepner J, **Link MP**, Laver J, Murphy S, Desai S, Schwenn M, Tarbell N, Fitzgerald TJ, Hutchison RE. ALK-negative cutaneous anaplastic large cell lymphoma (ALCL) in children frequently relapses. *Blood* 96:232b, 2000.
145. Crews KR, Liu T, Rodriguez-Galindo C, Pratt CB, Tan M, Panetta JC, Meyer WH, **Link MP**, Daw NC. High dose methotrexate (HDMTX) pharmacokinetics in osteosarcoma. *Proc Am Soc Clin Oncol* 20:371a, 2001 (Poster session).
146. Meyers P, Schwartz C, Bernstein M, Betcher D, Conrad E, Ferguson W, Gebhardt M, Goodman M, Goorin A, Grier H, Harris M, Healey J, Huvos A, Kleinerman E, Krailo M, **Link M**, Montebello J, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R. Addition of ifosfamide and muramyl tripeptide to cisplatin, doxorubicin and high dose methotrexate improves event free survival (EFS) in localized osteosarcoma (OS). *Proc Am Soc Clin Oncol* 20:367a, 2001 (Presented).
147. Schwartz CL, Bernstein M, Teot L, Devidas M, **Link M**. Cyclosporine A (CSA) to overcome multiple drug resistance in osteogenic sarcoma (OS): A Pediatric Oncology Group study (POG 9357). *Med Pediatr Oncol* 37:177, 2001. XXXIIIrd Annual Meeting of SIOP. Brisbane, October 10-13, 2001.
148. Granowetter L, Womer R, Devidas M, Perlman E, Shamberger R, **Link M**, Neff J, Marcus K, Sailer S, Goorin A, Arndt C, Dickman P, Gebhardt M, Grier H. Comparison of dose intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: A Pediatric Oncology Group-Children's Cancer Group Phase III trial. *Med Pediatr Oncol* 37:172, 2001. XXXIIIrd Annual Meeting of SIOP. Brisbane, October 10-13, 2001.
149. Smith RS, Chen Q, Hudson M, **Link M**, Kun L, Tarbell N, Weinstein H, Billett A, Marcus K, Donaldson SS. Prognostic factors in pediatric Hodgkin's disease. *Int J Radiation Oncol Biol Phys* 19:119, 2001.
150. Spunt SL, Hock LM, Ruymann FB, Qualman SJ, Donaldson SS, Rodeberg DA, Anderson JR, Crist WM, **Link MP**. Cyclophosphamide dose intensification during induction therapy is feasible but does not appear to improve the outcome of children and adolescents with intermediate risk rhabdomyosarcoma (RMS): A report from the Children's Oncology Group Soft Tissue Sarcoma Committee D9502 study. *Proc Am Soc Clin Oncol* 21:393a, 2002.

151. **Link MP**, Devidas M, Murphy SB, Behm FG, Hutchison R. Favorable treatment outcome of children with early stage large B-cell and anaplastic large cell lymphomas. Proc Am Soc Clin Oncol 23:795, 2004.
152. Bhatia S, Krailo M, Chen Z, Burden L, Dickman P, Grier H, **Link M**, Meyers P, Perlman E, Robison LL, Miser J. Therapy-related myelodysplasia/leukemia (t-MDS/AML) following treatment of children with Ewing sarcoma and primitive neuroectodermal tumor of bone (PNET). Proc Am Soc Clin Oncol 23:803s, 2005.
153. Donaldson SS, Tarbell NJ, Weinstein HJ, **Link MP**, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Hudson MM. End result of a prospective clinical trial with VAMP and low-dose involved-field radiation for pediatric patients with favorable early-stage Hodgkin's disease. Submitted.

**APPEARS THIS WAY  
ON ORIGINAL**

## INVITED PRESENTATIONS

Visiting Professor, Cleveland Clinic Foundation, November 1982.

"Lymphomas in Childhood".

St. Jude Children's Research Hospital, 19th Annual Clinical Symposium, February 22-23, 1985.

Research Seminar and Keynote Talk:

"The Role of Adjuvant Therapy in the Treatment of Osteogenic Sarcoma"

Third Meeting of the Jordan Medical Society, May 11-12, 1983, Amman, Jordan.

"Non-Hodgkin's Lymphoma in Childhood"

National Institutes of Health Consensus Development Conference on Limb-Sparing Treatment of Adult Soft Tissue Sarcomas and Osteosarcomas. Bethesda, Maryland. December 3-5, 1984.

"The Role of Adjuvant Chemotherapy in the Treatment of Osteosarcoma of the Extremity: Preliminary Results of the Multi-Institutional Osteosarcoma Study"

National Cancer Institute Sponsored Symposium on the Development of Folates and Folic Acid Antagonists in Cancer Chemotherapy. Tarpon Springs, Florida. January 23-26, 1986.

"Adjuvant Chemotherapy With High Dose Methotrexate in the Treatment of Osteosarcoma"

Annual Meeting of the American Society of Hematology, San Francisco, California. December 1986. Educational Session on Childhood Lymphomas.

"Biology of Non-Hodgkin's Lymphoma"

American Academy of Pediatrics--Frontiers in Pediatrics, San Francisco, California. July 13-15, 1986.

"Use of Monoclonal Antibodies in the Treatment of Leukemia/Lymphoma"

The Expanding Role of Folates in Cancer Chemotherapy. Presented at the University of Miami, University of Kansas Medical Center, UCLA School of Medicine, Tufts University School of Medicine, July-August, 1987

"High Dose Methotrexate and Leucovorin (HDMTX/LV) Rescue in the Treatment of Osteosarcoma"

American Academy of Pediatrics, New Orleans, LA, October 1987.

"Chemotherapy (vs. Bone Marrow Transplantation) in the Treatment of Acute Non-Lymphocytic Leukemia"

National Cancer Institute Sponsored International Symposium on Sarcomas, Tarpon Springs, Florida. October 8-10, 1989.

"Adjuvant Chemotherapy in the Treatment of Osteosarcoma. Results of the Multi-Institutional Osteosarcoma Study".

Visiting Professor, Memorial Sloan-Kettering Cancer Center, January 1988.

"Role of Adjuvant Chemotherapy in the Treatment of Osteosarcoma"

The Hackensack Medical Center. Topics in Pediatric Hematology and Oncology--Update 1989. Captiva Island, Florida, February 19-23, 1989.

"Osteogenic Sarcoma"; "Biology of Lymphoid Malignancies, Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia"

- The Jordan Cancer Society. First Cancer Conference. Amman, Jordan, March 21-24, 1989.  
 "Biology and Classification of Acute Lymphoblastic Leukemia", "Classification and Management of Pediatric Lymphomas", "Recent Advances in the Management of Acute Leukemia"
- Annual Meeting of the American Society of Clinical Oncology, May 21-23, 1989. Education Program "Meet the Professor" Lecture.  
 "Osteosarcoma"
- Thirteenth Annual Cancer Symposium of Scripps Research Hospitals, La Jolla, California. October 30-November 1, 1989.  
 "Lessons Learned from Lymphomas of Childhood"
- American Academy of Pediatrics Sponsored National Symposium on Bone and Soft Tissue Sarcomas, October 7-9, 1990.  
 "Role of Preoperative and Adjuvant Chemotherapy in Osteosarcoma"
- Visiting Professor, Pediatric Oncology Branch, National Cancer Institute, February 1, 1991.  
 "The Role of Chemotherapy in The Management of Osteosarcoma of the Extremity"
- American Cancer Society Workshop on Children with Cancer, Naples, Florida, September 5-6, 1991.  
 "The Laboratory-Clinical Interface in Research on Childhood Cancer"
- Osteosarcoma Research Conference 1991, Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania, October 16-18, 1991.  
 "The Role of Presurgical and Adjuvant Chemotherapy in Osteosarcoma of the Extremity"
- Annual meeting of the American Society of Pediatric Hematology/Oncology, Chicago, September 24-26, 1992.  
 Plenary session on childhood Non-Hodgkins Lymphomas (Michael Link, chairman).  
 "Staging and management of localized, favorable non-Hodgkin's lymphomas"
- Vail Cancer Treatment Conference, Vail, Colorado, March 8-12, 1993.  
 "Acute lymphoblastic leukemia in childhood: Biological features and their impact on prognosis and therapy"  
 "The non-Hodgkin's Lymphomas of childhood"  
 "Bone tumors of childhood: Osteosarcoma and Ewing's sarcoma"
- Twenty-fifth meeting of the International Society of Paediatric Oncology (SIOP), San Francisco, California, October 5-9, 1993.  
 "Early stage non-Hodgkin's Lymphoma: Current strategy and future prospects"
- Annual Meeting of the American Society of Clinical Oncology, May 14-17, 1994. Education Program "Meet the Professor" Lecture.  
 "Non-Hodgkin's lymphoma in children"
- First International Symposium on Multimodality Approaches for Limb Salvage of Extremity Sarcomas. Vail, Colorado, August 11-14, 1994.  
 "Current Status of Post-Operative Adjuvant Chemotherapy for Osteosarcoma"
- Third United States/Japan Clinical Trials Summit. Seattle, Washington, August 26-28, 1994.  
 "Adjuvant and Neoadjuvant Chemotherapy of Osteosarcomas"
- Annual Scientific Meeting of the American Society of Pediatric Hematology/Oncology. Chicago, Illinois, October 6-8, 1994.  
 "Osteogenic Sarcoma: The POG Experience"

The 8th Jordanian Medical Conference. Amman, Jordan, October 18-20, 1994.

“The Impact of Biological Features on Prognosis in Childhood Acute Lymphoblastic Leukemia”

“Progress in the Treatment of Non-Hodgkin’s Lymphomas in Children”

Fifth International Congress on Anti-Cancer Chemotherapy. Paris, France, January 31-February 3, 1995.

“The Development of Adjuvant Chemotherapy for Osteosarcoma”

“Update of Current Studies in Children with Osteosarcoma”

Current Concepts in Surgical Pathology. Stanford, California, September 27-29, 1995.

“Update on Treatment of Childhood Tumors”

Dana-Farber Cancer Institute 50th Anniversary Scientific Symposium. Boston, Massachusetts, October 30-November 1, 1997.

“Lessons Learned from the Non-Hodgkin’s Lymphomas of Childhood”

Monitoring of Clinical Trials: Sponsored jointly by the Department of Biostatistics, Harvard School of Public Health and Schering-Plough Research Institute. Boston, Massachusetts, May 28-29, 1998.

“A Clinician’s Perspective”

American Academy of Pediatrics, Section on Surgery. San Francisco, California, October 1998.

“The Non-Hodgkin’s Lymphomas of Childhood”

14<sup>th</sup> Annual Excalibur Round Table program of the American Cancer Society. San Francisco, California, August 4-6, 1999. “Childhood Cancer”

13<sup>th</sup> Ben Abelson Memorial Visiting Professor at Washington University School of Medicine and the Saint Louis Children’s Hospital. Saint Louis, Missouri, May 11-12, 2000. “The Non-Hodgkin’s Lymphomas of Childhood”

Food and Drug Administration. Oncology Drugs Advisory Committee, Bethesda, June 28, 2001. “Perspectives on Sarcomas”

American Society of Clinical Oncology/ American Association for Cancer Research Workshop on Methods in Clinical Cancer Research, Vail, Colorado, July 28 - August 3, 2001.

“Clinical Trials in Children with Cancer”

American Society of Clinical Oncology/ American Association for Cancer Research Workshop on Methods in Clinical Cancer Research, Vail, Colorado, July 27 - August 2, 2002.

“Clinical Trials in Children with Cancer”

First International Symposium on Childhood and Adolescent Non-Hodgkin’s Lymphoma. New York, New York, April 10-12, 2003. “Limited Stage Lymphoblastic Lymphoma: Therapeutic Dilemma”

American Society of Clinical Oncology/ American Association for Cancer Research Workshop on Methods in Clinical Cancer Research, Vail, Colorado, July 26 - August 1, 2003.

“Clinical Trials in Children with Cancer”

12<sup>th</sup> Annual Pediatric Cancer Research Foundation Memorial Lectureship. Children’s Hospital of Los Angeles. Los Angeles, California, January 19, 2004. “Progress in Therapy for Childhood Non-Hodgkin’s Lymphoma”